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Abstract 
 
The liver is an essential organ for maintaining homeostasis and is vital for 
storage, synthesis, oxidation, and recirculation of lipid in fed and fasted states. In 
response to fasting, fatty acids (FAs) flux from adipose tissue to the liver and are 
converted to acyl-CoAs for incorporation into complex lipids or transportation into 
the mitochondria for oxidation. The latter process is orchestrated by a group of 
proteins that are transcriptional targets of peroxisome proliferator activated 
receptor α (PPARα). However, little is known about hepatic acyl-CoA 
thioesterase 1 (ACOT1), a member of the broader acyl-CoA thioesterase family 
that catalyzes the conversion of acyl-CoAs back to FAs and coenzyme A. Thus, 
this research is aimed to understand the role of ACOT1 in fasting lipid 
metabolism. To investigate its physiological importance, we employed 
adenovirus-mediated knockdown, overexpression in tissue culture, as well as 
generation of a whole-body Acot1 knockout mouse line. Our results show that 
ACOT1 preferentially hydrolyzes acyl-CoA molecules that are destine for 
mitochondrial β-oxidation. As such, acute Acot1 knockdown results in reduced 
liver triglyceride (TG) and enhanced FA oxidation in vivo and in vitro. Increased 
FA oxidation correlated to greater hepatic glucose production and storage. 
Additionally, we determined that ACOT1 regulates PPARα by providing FA 
ligands. As such, supplementation with a PPARα synthetic ligand rescues the 
Acot1 knockdown phenotype. Furthermore, Acot1 overexpression increases 
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PPARα activity only when ACOT1 is catalytically active. Together these data 
suggest that ACOT1 regulates PPARα through its hydrolysis product. We also 
discovered that ACOT1 translocates to the nucleus during prolonged fasting, 
potentially to provide a local pool of FAs to activate PPARα. Thus, acute Acot1 
knockdown solicits enhanced FA oxidation, yet reduces PPARα target gene 
expression. Complications of this disconnect between metabolism and gene 
expression was evident by increased oxidative stress and inflammation, often 
seen in fibrotic and cirrhotic stages of non-alcoholic fatty liver disease (NAFLD), 
when Acot1 was knocked down. To further our investigation of ACOT1, we 
compared whole-body Acot1 knockout mice to their wild type littermates. We 
demonstrate that Acot1 knockout lead reduces adiposity, by decreasing 
adipocyte size and increasing adipocyte number. Acot1 knockout also reduced 
hepatic TG, providing protection from oxidative stress and inflammation that 
precedes TG accumulation. However, Acot1 knockout reduced glucose tolerance 
suggesting impaired glucose homeostasis. These results suggest Acot1 
knockout impaired lipid storage potential, increasing lipid intermediates, and 
contributing to glucose intolerance. Taken together, hepatic ACOT1 regulates FA 
oxidation and protects from oxidative stress and inflammation, whereas whole-
body ACOT1 contributes to lipid storage.   
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Hepatic Metabolism  
The liver is an essential organ for whole-body energy homeostasis during feeding 
and fasting. Hepatic metabolism orchestrates a delicate balance between energy 
storage and energy production dependent on the nutritional state (1). In the fed 
state, the liver is important for storing glucose as glycogen and synthesizing fatty 
acids (FAs) to be used at a later time. In the fasted state, the liver ensures 
adequate maintenance of blood glucose and provides ketones as an energy 
source for the brain and other organs (1).  
The liver is the primary organ responsible for the oxidation, synthesis, and 
distribution of lipids. Hepatic lipids can be stored as TG in lipid droplets oxidized 
through β-oxidation or secreted as very low-density lipoprotein (VLDL) (2). In the 
fed state, hepatic lipids are derived from the uptake of chylomicron remnants or 
are synthesized via de novo lipogenesis (DNL), the process of converting excess 
carbohydrates into FAs. DNL is orchestrated largely through two transcription 
factors, sterol response element binding protein 1c and carbohydrate response 
element binding protein. Insulin increases expression of sterol response element 
binding protein 1c, while glucose stimulates carbohydrate response element 
binding protein, increasing the transcription of glycolytic and lipogenic genes 
essential for DNL. During DNL, citrate from the tricarboxylic acid cycle is shuttled 
to the cytosol and serves as two carbon building blocks for new FAs. The initial 
step of FA synthesis is achieved by acetyl-CoA carboxylase forming malonyl-
CoA (3). Newly synthesized FAs, primarily palmitic acid, can be elongated or 
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desaturated and esterified to a glycerol backbone to form TG. TG can then be 
stored in lipid droplets or used for VLDL maturation and secretion. VLDL then 
enters circulation and distributes lipid to adipose depots for storage or other 
peripheral tissues for utilization (2).  
Conversely, during fasting, glucagon inhibits sterol response element 
binding protein 1c and subsequent FA synthesis (4). β-adrenergic stimulation 
induces lipolysis in adipose tissues, resulting in the release of non-esterified fatty 
acids (NEFAs) into circulation (5). Serum NEFAs are readily taken up by the liver 
through fatty acid transport proteins and cluster of differentiation 36 protein (6). 
These FAs are then converted to acyl-CoA molecules by a family of acyl-CoA 
synthetases (ACSL) (7) and are transported into the mitochondria through 
carnitine transfer protein 1α (CPT-1α), where they serve as a source of energy 
through β-oxidation (8). CPT-1α activity is inhibited by malonyl-CoA produced by 
DNL (3), which ensures that FAs are not being synthesized and oxidized 
simultaneously. FAs can be completely oxidized to CO2 or partially oxidized to 
ketone bodies that re-enter circulation (2). Importantly, hepatic FAs regulate their 
own metabolism by serving as signaling molecules that activate transcription 
factors necessary for these oxidative pathways (2).  
The liver also serves as a regulator of whole-body glucose homeostasis. 
In the fed state, the liver clears 30-40% of glucose coming from the digestive 
system (9), converting most to glycogen for storage. In mice, the liver can store 
up to 90mg of glycogen per gram of liver tissue (10). Once capacity is reached 
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excess glucose is converted to FAs through DNL as described above (3). During 
fasting, the liver maintains blood glucose through glycogenolysis and 
gluconeogenesis (1). Glycogenolysis is the breakdown of glycogen while 
gluconeogenesis is the synthesis of glucose from glycerol, pyruvate, lactate, or 
branch chained amino acids (1). During initial fasting, glycogen is the primary 
source of blood glucose, while gluconeogenesis is the primary source in 
prolonged fasting.  In mice, glycogen stores are depleted by 50% after 8 hours of 
fasting and by 12 hours are depleted by 80%. Reciprocally, gluconeogenesis and 
ketogenesis increase during 12 to 16 hours of fasting to compensate for 
glycogen loss (10). Human studies indicate a longer tolerance to fasting. 
Glycogen stores reach 50% after 22 hours of fasting and by 42 hours are roughly 
15%. Gluconeogenesis accounts for 50% of blood glucose at 22 hours of fasting 
and nearly all blood glucose by 42 hours (11,12). By 4 hours of fasting plasma 
NEFA levels begin to increase due to adipose lipolysis, promoting fatty acid 
oxidation in the liver and providing an energy source for gluconeogenesis. The 
presence of FAs inhibit glycogenolysis (13,14) while enhanced FA oxidation can 
increase gluconeogenesis (15). These studies suggest that FA oxidation is 
important for the activation of gluconeogenesis during fasting.  
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Non-Alcoholic Fatty Liver Disease 
Lipid imbalance can lead to hepatic lipid accumulation (6,16) which defines a 
disease known as non-alcoholic fatty liver disease (NAFLD). Imbalance can 
occur due to increased intake of dietary lipid, increased synthesis of FAs via 
DNL, or increased uptake of NEFA, as well as a reduction in VLDL secretion or 
reduced FA oxidation. These imbalances increase hepatic TG storage (16–18). 
In clinical studies, patients with increased hepatic lipid had TG stores that were 
derived from NEFA (60%), DNL (25%), and dietary lipid (15%) (19), suggesting 
that the major contributor to hepatic steatosis is NEFAs derived from adipose 
tissue lipolysis.  
NAFLD is an inclusive title for a spectrum of liver disease states that 
includes liver steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, 
and hepatocellular carcinoma (16). NAFLD is tightly correlated to a number of 
metabolic diseases including obesity, Type 2 Diabetes, and Cardiovascular 
Disease (20–23). Recent evidence suggests that one third of all Americans have 
NAFLD (23) and the prevalence and severity of the disease increases amongst 
overweight and obese populations (24). The progression of NAFLD is one of the 
leading causes of liver failure in the United States (20–22). Simple liver steatosis 
is considered a benign form of liver disease and lipid sequestered as non-toxic 
TG is an innate protective mechanism (25). Progressive states of NAFLD are 
marked by increased lipid intermediates that cause oxidative stress, 
mitochondrial dysfunction, and increase inflammation that lead to fibrosis, 
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cirrhosis, and insulin resistance (26,27). Classically, NALFD has been described 
by a two-hit hypothesis, in which the initial hit is hepatic steatosis, while the 
subsequent hit is the inflammation that progresses the disease (28). Recently, 
Tilg et al. have suggested a multiple hit model in which a sequential or co-
occurrence of lipid accumulation, mitochondrial dysfunction, inflammatory 
response, and ER stress propagates the progression of simple steatosis to 
NASH (25). Therefore the exact mechanism by which NAFLD progresses is not 
well defined by one pathway, because each pathway is able to propagate the 
next. As such, it is unclear which condition appears first when progressing from 
steatosis to NASH and fibrosis. However, current research shows that hepatic 
steatosis results in greater ketogenesis (29,30), suggesting that FA oxidation 
may contribute to the progression of NAFLD.  
In addition to nutritional and metabolic risk factors for NAFLD, hepatitis C, 
hepatotoxins, inflammatory bowel diseases, and drug toxicity can lead to 
progressive forms of liver disease (31). Once NAFLD progresses toward fibrosis 
and cirrhosis liver disease is irreversible. Current treatments include prevention 
of further damage through dietary intervention and exercise, while severe cases 
require liver transplantation (32). Due to the increasing prevalence and severity 
of progressive NAFLD, understanding the development and metabolic 
complications of simple steatosis is imperative. 
The western lifestyle is linked with the development of obesity and 
metabolic syndrome. It is predicted that as many as 80-90% of obese individuals 
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have NAFLD (33). To better understand the development of diet induced NAFLD, 
researchers have attempted to create animal models that mimic the disease. 
Classically, a methionine and choline deficient diet has been used. This diet 
exhibits signs of NAFLD including steatosis, inflammation, and fibrosis, but does 
not coincide with obesity and insulin resistance often seen in human subjects 
who develop NAFLD (34). On the other hand, use of a high fat diet, 45% fat, 
results in obesity and insulin resistance, but only causes hepatic steatosis. To 
achieve hepatic inflammation and fibrosis, mice would have to remain on a high 
fat diet for 15 months (34). More recently, a diet high in lard, cholesterol, and 
fructose resulted in 80% of mice developing NASH after 16 weeks (35). These 
mice also exhibited the metabolic complications that accompany obesity, creating 
a model very similar to human NAFLD. Another research group designed a rat 
model that mimicked human NAFLD by feeding a 75% fat diet for only 3 weeks 
(36). These models more closely mimics the disease progression seen in 
humans and can better predict what causes the transition from benign steatosis 
to more severe disease states, however few studies have yet to be performed 
utilizing these diets.  
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Regulation and Signaling of Hepatic Free Fatty Acids and Acyl-
CoAs 
The source of hepatic intracellular FAs includes uptake of circulating NEFA, 
synthesis from DNL, or products of TG lipolysis at the lipid droplet surface. To be 
susceptible for further metabolism, intracellular free FAs must be linked to 
coenzyme A (CoA) via a thioester bond forming an acyl-CoA. Acyl-CoAs serve 
as substrate for several lipid pathways, including oxidation, TG synthesis, and 
synthesis of more complex lipid species. ACSLs catalyze the formation of acyl-
CoAs, a reaction utilizing ATP, and prevents the efflux of FAs to maintain a 
concentration gradient for FA uptake (2,7). ACSL isoforms have varying 
intracellular locations, substrate preferences, and kinetics resulting in selective 
partitioning of FAs to specific pathways. Hepatic ACSL3 and ACSL5 are 
important for the conversion of de novo synthesized FAs to acyl-CoAs destined 
to be incorporated into TG (37). ACSL1 is the primary isoform in hepatic tissue 
and is present on the outer membrane of the mitochondria. ACSL1 is the 
important isoform for activation of FAs destined for β-oxidation in numerous 
tissues (38–40) yet hepatic knockout of ACSL1 has minimal effects on fatty acid 
oxidation (41). Thus, the major ACSL isoform involved in the shuttling of FAs to 
mitochondrial β-oxidation in the liver has yet to be identified. 
Free FAs and acyl-CoAs are considered lipotoxic compounds (2). 
Therefore, the conversion of FAs to acyl-CoAs and their subsequent metabolism 
is a rapid process. To maintain low levels of lipotoxic lipids, liver-specific fatty 
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acid binding protein (LFABP) can bind and transport free FAs as well as acyl-
CoAs (42). LFABP is important for the transportation of substrate to metabolic 
fates. Liver-specific knockout of LFABP results in a reduction in mitochondrial β-
oxidation, highlighting the importance of LFABP in trafficking FAs toward 
oxidation (43). LFABP has a high affinity for FAs reducing cellular concentrations 
of free FAs. Total liver non-esterified FAs is estimated to range around 100 nM to 
500 nM, with free FAs in the low nM range (44). Acyl-CoA binding protein binds 
acyl-CoAs (45,46) and promotes FA uptake and ACSL activity by removing 
feedback inhibition of free acyl-CoAs on ACSLs (47). Free cellular acyl-CoAs are 
kept at a concentration lower than 5 nM primarily due to rapid metabolism 
(45,46). The concentration of free FAs and acyl-CoAs fluctuates during circadian 
cues and fed and fasted states, being low during the feeding and reaching the 
upper limits during fasting (48). The activity of these enzymes and binding 
proteins regulates the levels and locations of acyl-CoAs and FAs, which likely 
impacts their effects in cells as discussed below. 
Hepatic FAs and acyl-CoAs are prominent signaling molecules important 
for the activation of transcription factors involved in lipid metabolism. A major 
class of transcription factors involved in lipid metabolism are peroxisomal 
proliferator-activated receptors. The primary isoform involved in the 
transcriptional regulation of proteins involved in hepatic FA disposal is PPARα 
(44). Activated PPARα forms a heterodimer with retinoic x receptor and can 
induce transcription by binding to PPAR response elements in the promoter 
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region of target genes (49). A wide variety of lipid species serve as ligands for 
PPARα activation.  Saturated and monounsaturated FAs ranging from 14-20 
carbons (44,50), polyunsaturated fatty acids, eicosanoids (51), as well as 
phosphatidylcholine species (52) activate PPARα. As such, different 
physiological conditions that result in high concentrations of these lipid species 
may be predictive of PPARα activation. NEFA liberated from adipose tissue are 
taken up by the liver and serve as endogenous ligands for activation of PPARα 
during fasting (44). LFABP has been suggested to traffic FAs to the nucleus for 
signaling, yet in vivo and in vitro data showed mixed results of LFABP on PPARα 
activation (43,53). As such, the mechanism by which FAs translocate to the 
nucleus and serve as ligands to PPARα is not well characterized. Both long chain 
FAs as well as long chain acyl-CoAs are present in the nucleus (54,55). 
Palmitoyl-CoA antagonizes PPARα activity by inhibiting its binding to co-factors 
and DNA (55,56), suggesting that controlling the inter-conversion of FAs and 
acyl-CoAs, particularly in the nucleus, may have a large influence on PPARα 
activity. 
Another transcription factor that exhibits ligand binding to long chain FAs 
is hepatic nuclear factor 4α (HNF4α). HNF4α is a nuclear transcription factor 
present in hepatocytes that is necessary for cells to maintain the hepatic 
phenotype (57). HNF4α is important for the transcription of gluconeogenic genes 
through interaction with peroxisome proliferator-activated receptor gamma 
coactivator 1α (PGC1α) (58,59), as well as genes involved in lipoprotein 
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synthesis and secretion (60). Binding of FAs to HNF4α is strong, yet has no 
known affect on activity of the transcription factor (60). Conversely, HNF4α also 
exhibits ligand binding for acyl-CoAs, various acyl-CoA species can either be 
inhibitors or activators. Importantly, palmitoyl-CoA is a known activator of HNF4α 
(61). Thus, FAs and acyl-CoAs serve as important signaling molecules that 
influence hepatic energy metabolism. 
Patients with NAFLD have elevated serum NEFA and enhanced liver 
uptake of NEFA (62). It is suggested that an accumulation of intracellular FAs 
causes lipotoxicity, contributing to the progression of NAFLD (18,63). 
Interestingly, monounsaturated FAs such as oleic and palmitoleic acid do not 
have the hepatotoxic effects as their saturated counterparts, stearic and palmitic 
acid. This is primarily due preferred esterification of monounsaturated fatty acids 
into TG, sequestering them in non-toxic lipid storage (64). In cell culture, 
saturated FAs are capable of increasing reactive oxygen species (ROS) and 
subsequently activating the c-Jun NH2-terminal kinase apoptotic pathway in 
hepatocytes (65,66). Use of etomoxir, a CPT1α inhibitor, rescues palmitate-
induced c-Jun NH2-terminal kinase activation, indicating oxidation of palmitic 
acid is the source of ROS and apoptosis (66). Yet a physiological mix of both 
monounsaturated and saturated fatty acids prevents the apoptotic pathway 
caused by saturated fatty acids. Thus, maintaining a delicate balance of 
intracellular free FAs provides necessary ligands for PPARα activation while 
simultaneously minimizing lipotoxic effects of free FAs. 
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Oxidation of Hepatic Fatty Acids 
The liver is an oxidative organ, which carries out several pathways involved in FA 
oxidation. A large majority of liver FA disposal is achieved through mitochondrial 
β-oxidation. Cytosolic short and medium chain acyl-CoAs can diffuse through the 
mitochondrial membrane, while longer chain (12-20 carbons) acyl-CoAs require 
transport through CPT-1α present on the outer membrane of the mitochondria 
(67). Once in the mitochondrial matrix, acyl-CoAs are metabolized to acetyl-CoA 
molecules by means of β-oxidation, producing FADH2 and NADH, which donate 
electrons to the electron transport chain (ETC) (2).  Acetyl-CoAs produced from 
fatty acid oxidation can enter the tricarboxylic acid cycle for complete oxidation to 
CO2 or alternatively, excess acetyl-CoAs can be metabolized to ketone bodies in 
the mitochondrial matrix (2).  3-hydroxy-3-methylglutaryl-CoA synthase 2 
catalyzes the initial rate-limiting step in ketone body synthesis, converting acetyl-
CoAs to 3-hydroxy-3 methylglutaryl-CoA (68). 3-hydroxy-3-methylglutaryl-CoA is 
then converted to acetoacetate and finally β-hydroxybutyrate (69). Ketone bodies 
are released from hepatocytes and re-enter circulation, serving as energy 
sources for other tissues. Given that the liver is a sole source of ketone bodies 
(70), the concentration of β-hydroxybutyrate, the primary circulating ketone body, 
serves as a marker for hepatic mitochondrial β-oxidation and ketogenesis. 
As discussed previously, PPARα is important for the activation of genes 
involved in FA oxidation, including mitochondrial β-oxidation genes CPT1α and 
3-hydroxy-3-methylglutaryl-CoA synthase 2, rate-limiting steps for mitochondrial 
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FA uptake and ketogenesis, respectively (67,68). Another important nuclear 
transcriptional cofactor is PGC1α, important for FA oxidation and mitochondrial 
biogenesis (71). It has been demonstrated that PGC1α serves as a co-activator 
of PPARα enhancing transcription of genes involved in FA oxidation (72). 
Additionally, PGC1α acts as a co-activator to estrogen-related receptor α, 
promoting mitochondrial biogenesis (59,73). Therefore, simultaneous activation 
of both PPARα and PGC1α are essential for maximal mitochondrial oxidative 
capacity during fasting. 
 
Mitochondrial ROS Generation 
Normal mitochondrial oxidation produces a mild stress on the cell resulting in the 
production of ROS, predominantly superoxide (74). However, ROS production is 
balanced by mitochondrial antioxidant activity that protects the mitochondria from 
oxidative stress. Superoxide dismutase catalyzes the conversion of superoxide to 
hydrogen peroxide, which can then safely be degraded to water and oxygen by 
antioxidant enzymes, glutathione peroxidase and peroxiredoxin (75). During 
times of increased FA oxidation, ROS production can exceed antioxidant 
capacity. A high ratio of ATP/ADP and NADH/NAD+ reduces ATPase activity, 
and causes an increase in the proton gradient (76). Increased membrane 
potential can cause feedback inhibition of the proton pumps in the ETC (77). 
Intermediates in the ETC, primarily at Complex I and III, can then transfer 
electrons to oxygen forming superoxide (74). ROS production leads to 
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mitochondrial DNA and protein damage as well as membrane permeabilization 
and release of apopototic proteins (78), resulting in mitochondrial dysfunction. 
Superoxide is a highly reactive molecule and can cause the formation of lipid 
peroxides. Downstream metabolites of lipid peroxidation, such as 
malondialdehyde and 4-hydroxynonenal, can activate stellate cells that produce 
collagen and α smooth muscle actin (79). Malondialdehyde and 4-
hydroxynonenal also activates inflammatory pathways such as the transcription 
factor, nuclear factor- κB (28,80). Conversely, inflammatory cytokine tumor 
necrosis factor alpha (TNFα) can be produced in hepatocytes and by Kupffer 
cells in the liver during an immune response. TNFα can cause mitochondrial 
swelling and result in membrane bursting. When mitochondrial membranes burst 
there is a disconnect between cytochromes in the electron transport chain 
leading to superoxide production and release of apoptotic proteins (81–83). 
During times of oxidative stress, many cell types exhibit expression of 
uncoupling protein 2 (UCP2) present on the inner membrane of the mitochondria 
(84). UCP2 serves as a proton leakage source therefore uncoupling the ETC 
from ATP synthesis. UCP2 has the potential for ameliorating some of the 
oxidative pressure on mitochondrial respiration (85). UCP2 expression has been 
shown to protect neurons from apoptosis (86).  Similarly, overexpression of 
UCP2 in cardiomyocytes protects cells from cardiomyopathy by improving FA 
oxidative capacity (85). In normal physiological conditions, hepatocytes do not 
express UCP2(84), yet under acute and chronic stress expression is enhanced 
  15 
(87). UCP2 overexpression lowers the oxidative burden on hepatic mitochondria 
thereby protecting cells from oxidative damage (88). NASH in humans and rats 
increases expression of UCP2, which serves as a marker for oxidative stress. 
An increase in cellular ROS and lipid peroxides as well mitochondrial 
dysfunction is a hallmark of NAFLD (26,89,90). Mitochondrial dysfunction, ROS 
production, and inflammation is a classic “chicken and egg” scenario where each 
can cause the other, yet all three usually occur simultaneously making it difficult 
to distinguish what came first (79,91). An increase in FA oxidation has been 
described as a compensatory mechanism to handle excess FA accumulation 
(92,93). However, the pathological effect of increased mitochondrial FA oxidation 
has yet to be studied as a potential cause for ROS production in the progression 
of NAFLD. 
 
Acyl-CoA Thioesterase Family 
As previously stated, FAs must be activated to acyl-CoAs for subsequent 
metabolism. However, a family of acyl-CoA thioesterases (ACOTs) catalyze the 
reverse of this reaction, hydrolyzing the thioester bond resulting in the production 
of coenzyme A and a FA. As such, it is suggested that ACOTs create a futile 
cycling with ACSLs, due to the use of ATP to form acyl-CoAs (94). ACOTs are 
ubiquitously expressed in many tissues and varying organelles. Additionally, 
ACOTs have varying substrate specificity, from acetyl-CoA to short, medium, and 
long chain acyl-CoAs as well as branch chain acyl-CoAs and bile acids (95).  
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ACOT activity was first discovered in the cytosol of rat liver, in which 
palmitoyl-CoA hydrolysis was measured and the enzyme responsible was termed 
palmitoyl-CoA hydrolase (96).  This led to the identification of two cytosolic and 
two mitochondrial isoforms that differ in molecular weight. The light chain 
thioesterases (~40kD) were termed cytoplasmic thioesterase I and mitochondrial 
thioesterase I, while the heavier chains (~110kD) were named cytoplasmic 
thioesterase II and mitochondrial thioesterase II (97). This was the first distinction 
between what is now known as Type I and Type II thioesterases. Type I 
thioesterases are smaller and exhibit 40% homology to N-acyl-transferases, yet 
do not possess acyl-transferase activity (98). They possess a β-sandwich domain 
and an α/β hydrolase fold (98).  Type I thioesterases consist of ACOTs 1-6, 
which vary in tissue expression and cellular localization (99). Type II 
thioesterases (ACOT7-15) are distinguishable from Type I thioesterases because 
they are larger and possess a hotdog fold domain and a steroidogenic acute 
regulatory transfer domain (99,100). 
ACOTs are present in organelles involved in lipid shuttling and oxidation 
including cytosol, mitochondria, and peroxisomes. Peroxisomal ACOTs include 
both Type I and Type II isoforms, ACOT3, ACOT4, ACOT5, ACOT6, ACOT8 and 
ACOT12 (98). PPARα regulates the expression of peroxisomal ACOTs (98). 
Peroxisomal ACOTs, primarily those responsible for the hydrolysis of long and 
medium chain acyl-CoAs. ACOT3, ACOT5, and ACOT8 are speculated to be 
involved in FA exportation from the peroxisome for further metabolism in the 
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mitochondria (98). ACOT8 hydrolyzes a wide spectrum of acyl-CoA molecules 
varying in chain length, saturation, and branching. ACOT8 activity is inhibited by 
high levels of peroxisomal coenzyme A and is the only ACOT isoform that is 
inhibited by CoA (101).  Acetyl-CoA products from peroxisome β-oxidation are 
substrates for ACOT12, which is speculated to play a vital role in shuttling acetyl-
CoAs out of the peroxisome to be used for cytosolic DNL (102). ACOT2, 
ACOT13, and ACOT15 are the primary mitochondrial isoforms. ACOT2 is 
present in the mitochondrial matrix and promotes mitochondrial β-oxidation (103). 
ACOT13 is located on the outer mitochondrial membrane and is speculated to be 
important for the cleavage of acyl-CoAs, generating a pool of FAs that serve as 
substrate for shuttling into the mitochondria through the ACSL1-CPT1 complex 
(104). ACOT15 is present in the mitochondrial matrix and is essential for 
cardiolipin synthesis and mitochondrial structure (105). 
In humans ACOT1 and ACOT7 are cytosolic isoforms, yet ACOT1 is the 
only cytosolic Type I acyl-CoA thioesterase in mice (106), while ACOT7 is the 
primary cytosolic Type II thioesterase. ACOT7 is present in the brain and is 
important for maintaining adequate neuronal FA oxidation (107). ACOT1 is 
primarily expressed in the liver, kidney, and heart and shares 93.7% homology to 
mitochondrial ACOT2 (99). ACOT2 is slightly larger than ACOT1 due to its 42 
amino acid N-terminal mitochondrial target signal (99). However, when compared 
on a Western blot, ACOT2 runs below ACOT1 (108), indicating some potential 
post translational modification. It is believed that ACOT1 and ACOT2 share 
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similar activity but are distinct based on their cellular localization.  
 
Acyl-CoA Thioesterase 1 
Acyl-CoA Thioesterase 1 was first identified as palmitoyl-CoA hydrolase in rat 
livers by Yamada et al. in 1994 (109). It was then classified as the low molecular 
weight cytosolic thioesterase I (CTE-1) (97), which today correlates to its Type I 
thioesterase classification. Recombinant ACOT1 has demonstrated substrate 
preference toward long chain saturated FAs ranging from 12 to 20 carbons long 
(110). Activity toward monounsaturated fatty acids is half that of the saturated 
form and very little activity is detected towards polyunsaturated fatty acids (110). 
ACOT1 has a Km of 2.6 µM, suggesting a high affinity to acyl-CoAs. High 
concentrations of long chain acyl-CoAs, greater than 5 µM, inhibits ACOT1 
activity (110).  ACOT1 has a basic α/β hydrolase characteristic of Type I 
thioesterases, in which a beta sheet meets an alpha helix creating a sharp γ turn 
pocket (111). The catalytic triad consists of Serine232, Asp324, and His358. The 
serine motif consists of GxSxG, which is characteristic of all Type I acyl-CoA 
thioesterases (110). Mutation of any three of these residues result in complete 
loss of ACOT1 thioesterase activity (110). 
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Transcriptional Regulation of ACOT1 
Acot1 is a target gene of PPARα (112). Indeed, Acot1 is the most highly induced 
gene in response to peroxisome proliferators, such as clofibrate (113). As such, 
Acot1 expression is induced during times of enhanced FA oxidation 
(97,106,113). Acot1 is transcriptionally regulated by both PPARα and HNF4α 
through a distal response element (DRE-1) in the promoter region of the gene 
(112). HNF4α negatively regulates Acot1 expression; liver knockout of HNF4α 
resulted in a 15-fold increase in Acot1 expression (112). During fasting PPARα 
displaces HNF4α on these regulatory regions of the gene and promotes 
transcription of Acot1. This competitive binding to the Acot1 DRE-1 is dependent 
on ligand binding to PPARα and enhanced affinity to the DRE-1 over HNF4α 
(114). Pparα-null mice express ACOT1 protein during fasting but not with 
clofibrate treatment (115). In addition, liver-specific Pparα knockout mice also 
express Acot1 during fasting (116). Together these studies suggest that Acot1 
expression is partially independent of PPARα during fasting.  
In addition to PPARα and HNF4α, circadian regulatory proteins PAR 
domain basic leucine zipper proteins exhibit transcriptional regulation over 
ACOTs 1-4(117). As such, whole-body knockout of PAR domain basic leucine 
zipper proteins results in a decrease in circadian expression of these Acots. 
Interestingly, PPARα and target transcripts were also reduced (118). These 
results highlight a potential feed forward loop in which ACOTs may respond to 
circadian cues to produce ligands that promote PPARα activation and 
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subsequent transcription of Acots. Others have speculated that ACOTs are 
responsible for providing FA ligands for PPARα activation (101,106), however 
only a few studies have evidence to support this theory. Muscle mitochondrial 
ACOT2 was suggested to produce FAs that transport through UCP3 and serve 
as signaling molecules during excessive oxidation (119). Similarly, over-
expression of ACOT2 in mouse liver increased mitochondrial β-oxidation as well 
as expression of genes involved in FA oxidation (103). The exact mechanism for 
how ACOTs provide ligands that activate PPARα has not been elucidated. To 
date, the involvement of cytosolic ACOT1 in providing FAs ligands has not yet 
been characterized. Yet ACOT1 activity toward long chain saturated acyl-CoAs 
(110) suggests potential production of long chain saturated fatty acid ligands 
known to activate PPARα (50).  
 
ACOT1 Response to Diet and Disease 
Although the physiological relevance of ACOT1 has not yet been studied in the 
liver, ACOT1 has shown physiological relevance in response to diet and disease 
in other tissues. Fat-free diets reduce the expression of Acot1 in rodent models, 
independent of PPARα activity (115). Rats placed on a high fat diet had a 3 fold 
higher concentration of ACOT1 in heart and Type II muscle during fasting 
compared to those on a low fat diet (120). Another study indicated that 20 weeks 
on a high fat diet increased ACOT1 protein 5-fold compared to low-fat diet. 
These effects were seen independent of metabolic complications due to a high 
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fat diet (120). Another study feeding a 20% partially hydrogenated fat diet to rats 
for 29 days demonstrated a 2-fold increase in cytosolic thioesterase activity in the 
liver (121). Similarly, alloxen diabetic mice have demonstrated an increased 
expression of cytosolic thioesterase activity in the liver (122). A recent study by 
Ellis et al. suggests that in the liver ACOT1 protein concentration increases 
during high fat and ketogenic diets (94). These studies demonstrate the 
importance of dietary lipid in the expression and activity of ACOT1 and that 
disease states can impact Acot1 expression.   
Acot1 expression in pre-adipocytes is high, but expression diminishes with 
differentiation, highlighting a potential role in controlling levels of FA oxidation 
during adipocyte development to increase lipid storage (123,124). ACOT1 activity 
has been studied more extensively in the heart. Leptin receptor deficient db/db 
mice, which develop severe obesity-related diseases, have heightened protein 
levels of ACOT1 in the heart (125). In an insulin resistant state, animals can 
develop diabetic cardiomyopathy in which the heart becomes enlarged and 
inflamed due to an enhanced use of FAs as the primary energy source (126). 
Overexpression of Acot1 in cardiomyocytes improves diabetic induced 
cardiomyopathy in mice by reducing FA oxidation and improving ROS levels. 
These effects were mitigated through enhanced PPARα and PGC1α signaling 
(125). In addition, Acot1 overexpression was protective against heart failure 
during sepsis (127). This highlights the potential involvement of ACOT1 in 
minimizing oxidative stress and promoting mitochondrial capacity, by removing 
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substrate to mitochondrial β-oxidation and increasing signaling toward PPARα 
and PGC1α. Thus, ACOT1 expression may be elevated in diabetes and 
cardiomyopathy as a protective mechanism. Investigating the role of ACOT1, the 
primary hepatic cytosolic ACOT, in hepatic lipid metabolism may provide insight 
on how oxidative capacity regulated by ACOT1 mitigates progression of liver 
steatosis to NASH and fibrosis. Despite high expression in the liver, the 
physiological significance of ACOT1 in the progression of NAFLD has not been 
investigated. 
 
Current Objectives 
The progression of NAFLD from simple steatosis to inflammation, fibrosis, 
and cirrhosis is described as the two-hit hypothesis. As such, steatosis is the first 
hit, then the metabolic complications that progress the disease are considered 
the second hit (28). However, to date, the mechanism of how steatosis leads to 
oxidative stress, inflammation, and fibrosis is poorly understood. Recent research 
suggests that steatosis leads to greater FA oxidation in the liver (29,30). 
However, the contribution of excess FA oxidation to oxidative stress and 
inflammation is poorly understood, yet in vitro studies suggest that oxidation of 
saturated FAs contributes to oxidative stress (66).  
Understanding the intricate regulation of FA and acyl-CoA molecules 
during fasting is imperative to elucidating the mechanisms by which hepatic 
steatosis becomes more severe. Acyl-CoA thioesterases are a class of enzymes 
  23 
that are understudied and may provide insight into how FA metabolic pathways 
are regulated during feeding and fasting. In order to understand the fundamental 
importance of hepatic acyl-CoA thioesterase activity, we investigated the 
physiological relevance of ACOT1 in the forthcoming chapters of this 
dissertation.  
 
Figure 1. ACOT1 in hepatic lipid metabolism. Hepatic FAs can be taken up 
into the cell, synthesized by DNL, or cleaved from TG pools in lipid droplets. 
Acyl-CoA synthetase family members (ACSL) utilize ATP to form thioester bonds 
between free FAs and coenzyme A. Acyl-CoAs are then substrate to 
mitochondrial β oxidation, TG synthesis for VLDL packaging, or the synthesis of 
other lipid species such as phospholipids. ACOT1 catalyzes the reverse reaction, 
cleaving acyl-CoAs back to free FAs. Free FAs are known to activate PPARα and 
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increase expression of genes involved in FA oxidation.  
The work in this thesis investigates the physiological importance of 
ACOT1 in fasting hepatic metabolism. The second chapter investigates ACOT1 
via adenovirus-mediated knockdown of ACOT1 for one week during feeding and 
fasting and under different dietary conditions. Acute Acot1 knockdown answers 
the questions: How does ACOT1 regulated lipid metabolism? How does ACOT1 
regulate nuclear signaling to PPARα? How does ACOT1 regulate hepatic 
glucose metabolism? And lastly, how does hepatic lipid metabolism contribute to 
oxidative stress and inflammation? The third chapter explores the effects of 
whole-body Acot1 knockout in male and female mice fed a purified control or a 
high fat diet. The third chapter answers the questions: How does whole-body 
Acot1 ablation impact lipid storage in adipose and liver? How does long-term 
Acot1 knockout affect whole-body energy expenditure in relation to lipid and 
glucose metabolism?   
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CHAPTER 2 
 
Acyl-CoA Thioesterase 1 (ACOT1) 
Regulates PPARα  to Couple Fatty 
Acid Flux With Oxidative Capacity 
During Fasting 
 
 
 
Mallory Franklin wrote this chapter in its entirety 
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Hepatic acyl-CoA thioesterase 1 (ACOT1) catalyzes the conversion of acyl-CoAs 
to fatty acids (FAs) and coenzyme A. The physiological importance of hepatic 
ACOT1 has yet to be determined. Therefore, we sought to determine the role of 
ACOT1 in hepatic lipid metabolism in C57Bl/6J male mice one week following 
adenovirus-mediated Acot1 knockdown. Acot1 knockdown reduced liver 
triglyceride (TG) due to enhanced TG hydrolysis and subsequent FA oxidation. In 
vitro experiments demonstrated that Acot1 knockdown led to greater TG turnover 
and FA oxidation, suggesting that ACOT1 is important for controlling the rate of 
FA oxidation. Despite increased FA oxidation, Acot1 knockdown reduced the 
expression of peroxisome proliferator-activated receptor α (PPARα) target genes. 
Similarly, overexpression of Acot1 increased PPARα reporter activity, an effect 
that was dependent on ACOT1 catalytic activity, suggesting that ACOT1 
regulates PPARα by producing FA ligands. Moreover, ACOT1 exhibited partial 
nuclear localization during fasting and cAMP/PKA signaling, indicating a potential 
local regulation of PPARα. As a consequence of increased FA oxidation and a 
reduction in PPARα activity, Acot1 knockdown enhanced hepatic oxidative stress 
and inflammation. The effects of Acot1 knockdown on PPARα activity, oxidative 
stress, and inflammation were rescued by supplementation with Wy-14643, a 
synthetic PPARα ligand. Male mice fed a high fat diet for three months prior to 
Acot1 knockdown exhibited greater oxidative stress, inflammation, and markers 
of fibrosis, a phenotype normally not seen with high fat diet. Finally, Acot1 
knockdown also increased gluconeogenesis and glycogen storage, which was 
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rescued with Wy-14643, suggesting that PPARα signaling is important for 
glucose homeostasis. Taken together, we demonstrate that ACOT1 regulates 
fasting hepatic metabolism by balancing FA oxidative flux and oxidative capacity, 
which protects from oxidative stress and regulates glucose homeostasis. 
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Introduction 
During times of fasting, FAs are released from adipose tissue and readily taken 
up by the liver where they can be oxidized in the mitochondria via β-oxidation 
(1,2). In order to be transported into the mitochondria, FAs must be converted to 
acyl-CoAs by long chain acyl-CoA synthetases (3). A family of acyl-CoA 
thioesterases catalyze the reverse reaction – the hydrolysis of the fatty acyl-CoA 
thioester bond resulting in the production of coenzyme A and a free FA (4). This 
reaction seemingly removes acyl-CoAs from mitochondrial β-oxidation. In the 
liver, ACOT1 is the primary cytosolic thioesterase isoform (5). PPARα induces 
Acot1 expression through a distal response element in the promoter region of the 
gene (6,7). However, fasting induces Acot1 expression in whole-body Pparα-null 
mice as well as liver-specific Pparα knockout mice (6,7), suggesting that PPARα 
is sufficient, but not necessary for Acot1 expression. Therefore, ACOT1 is 
speculated to be involved in FA trafficking during periods of increased hepatic FA 
influx and oxidation (8,9). 
PPARα is a transcription factor that governs the expression of genes 
involved in FA oxidation and is necessary to increase FA oxidative capacity 
during times of fasting (7). A wide variety of lipid species are speculated to serve 
as ligands for PPARα activation including free FAs (10–12). In addition to its role 
in FA oxidation, PPARα promotes the expression of anti-inflammatory genes (13) 
as well as suppresses expression of inflammatory genes (14). As such, PPARα 
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ligands are potential therapeutic agents for the prevention or treatment of 
inflammation (14).  
Mitochondrial FA oxidation produces a mild amount of ROS at complex I 
and III of the electron transport chain (15). This ROS production is balanced by 
antioxidant activity that protects the mitochondria from oxidative stress (16). 
However, during times of increased FA oxidation, increased membrane potential 
can lead to ROS production that can exceed antioxidant capacity leading to 
oxidative stress (15,17,18). Regulating the rate of FA oxidation in the cell is 
critical for minimizing ROS and oxidative stress that can occur during times of 
increased oxidation. Overexpression of Acot1 in cardiomyocytes reduces FA 
oxidation and ROS production in mice with diabetic cardiomyopathy (19). These 
data suggest a potential involvement of ACOT1 in promoting oxidative capacity 
through substrate regulation and signaling.  
During prolonged fasting, the liver is an essential organ for maintaining 
blood glucose. In the initial stages of fasting, hepatic glycogen is broken down to 
maintain blood glucose. Once glycogen stores are depleted, hepatic 
gluconeogenesis continues to provide glucose (20). Gluconeogenesis is an 
energy-demanding pathway, which is largely driven by ATP produced from 
hepatic FA oxidation. Therefore alterations in hepatic FA oxidation, could affect 
glucose production and blood glucose levels during prolonged fasting (21).  
Despite high expression in the liver during fasting, the involvement of 
ACOT1 in lipid metabolism has yet to be characterized. Herein, we identify 
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ACOT1 as a key enzyme that links FA flux and trafficking to PPARα signaling, 
ROS, and inflammation, as well as secondary regulation of hepatic glucose 
production. 
 
Research Design and Methods 
Mouse handling. The Institutional Animal Care and Use Committee of the 
University of Minnesota approved all protocols used in this study. Seven to nine 
week old male C57BL/6J mice were purchased from Harlan Laboratories 
(Madison, WI) and housed in a controlled temperature (20°-22°C) and light (12 
hrs light/12 hrs dark) vivarium. Mice had free access to water and were fed a 
purified diet (TD.94045) from Harlan Teklad (Madison, WI).  One week before 
sacrifice, mice received a tail vein injection of an adenovirus harboring either 
scramble short-hairpin RNA (shRNA) described previously (22) or shRNA 
targeted to Acot1 mRNA. Acot1 shRNA adenovirus was generated from Open 
Biosystems (Huntsville, AL) based on accession number NM_012006.2 
(antisense sequence AAACACTCACTACCCAACTGT). For the studies involving 
Wy-14643, mice were fed the purified diet supplemented with 0.1% WY-14643 
(Selleckchem, Houston, TX), a synthetic PPARα ligand, for 7 days (23) An 
additional group of mice were fed a 45% high fat diet (TD.06415) for 12 weeks 
prior to a tail vein injection of the adenovirus treatment. One week post 
transfection all mice were fasted overnight (16 hrs) and harvested unless noted 
otherwise. 
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In vitro isotope experiments.  Three days post adenovirus injection, mice were 
fasted overnight (16 hrs) and primary hepatocytes were isolated via collagenase 
perfusion and plated on collagen-coated plates. Hepatocytes were cultured in 
insulin/serum free M199 media to mimic fasting conditions. All experiments were 
carried out the same day after a 4-hour plating period. Cells were pulsed with 
trace [14C]oleate along with 500 µM unlabeled oleate bound to BSA (3:1 molar 
ratio) for 2 hours. A subset of wells were harvested to measure radiolabel 
incorporation into cellular TG (pulse) and the remaining wells were given 
radiolabel free media for 6 hours before harvest (chase). Cells and media were 
harvested to quantify isotope in cellular TG, media TG, and media acid soluble 
metabolite (ASM) fractions as previously described (24,25). 
 
TG hydrolase activity. TG hydrolase activity was measured from tissue lysates 
from control and Acot1 knockdown mice. Lysis buffer consisted of 20 mM Tris-
HCl, 150 mM NaCl, and 0.05% Triton X-100, pH 8.0. Lysates were spun at 
15,000xg for 15 minutes. Infranatant was collected and mixed with 1,2-Di-O-
lauryl-rac glycerol-3-(glutaric acid 6-methylresorufin ester) and incubated at 30°C 
for 1 hour. Kinetic readings were taken every 2 minutes at 530 nm excitation and 
590 nm emission. Readings were compared to a standard curve generated with 
free resorufin.  
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Serum β-hydroxybutyrate. Serum was harvested after a 16 hour overnight fast. 
Serum β-hydroxybutyrate was assessed using β-hydroxybutyrate LiquiColor Kit 
(Stanbio Laboratory, Boerne, TX).  
 
RNA isolation and analyses.  mRNA was isolated from tissue or cells using 
Trizol Reagent (ThermoFisher, Waltham, MA) according to manufacturer’s 
protocol. cDNA was generated using SuperScript®VILO (Invitrogen, Carlsbad, 
CA). Quantitative real-time polymerase chain reaction was performed using 
SYBR Select (ThermoFisher, Waltham, MA).  
 
Protein preparation and Western blotting. Protein was isolated from 
hepatocytes and liver tissue in lysis buffer and quantified by BCA.  ACOT1 
protein was determined by Western blotting using 80 µg of protein.  Following 
SDS-PAGE, proteins were transferred to a PDVF membrane and probed for 
ACOT1 with a custom antibody. The Mus musculus ACOT1/ACOT2 antibody 
was developed in rabbit by injecting the antigen CSVAAVGNTISYKDET-amide 
(21st Century Biochemicals, Marlboro, MA). 
 
ROS determination. Cellular ROS and reactive nitrogen species (RNS) was 
determined using the OxiSelect In Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc., 
San Diego, CA) in which dichlorodihydrofluorescin reacts with ROS or RNS to 
produce fluorescent 2’,7’-dichlorodihydrofluorescein. Readings were measured at 
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480 nm excitation and 530 nm emission and compared to a standard curve 
generated with stock 2’,7’-dichlorodihydrofluorescein solution. 
 
Plasmids and cloning. DsRed-Express N1 plasmid was purchased from 
Clonetech (Mountain View, CA). Acot1 cDNA was amplified from a pCMV6 Acot1 
plasmid purchased from Origene (Rockville, MD). Acot1 cDNA was cloned into 
the multiple cloning site of DsRed-Express N1 by restriction enzyme digestion 
and T4 DNA ligase ligation. S232A point mutation was achieved using the 
QuikChange site-directed mutagenesis kit from Agilent and primers previously 
reported (9).  
 
Cell and tissue imaging.  Tissue sections were either froze in Tissue-Tek® 
O.C.T. (VWR, Eagan, MN) or fixed in 10% formalin and subsequently paraffin 
embedded. Slides were deparaffinized and blocked in 3% BSA, incubated with 
ACOT1 antibody overnight, stained with DAPI, and mounted. 
Immunohistochemistry for Cd45 was determined as well as Oil Red O and H&E 
stains from the University of Minnesota’s BioNet Histology and IHC Lab. AML12 
cells were cultured in DMEM media containing 10% FBS, 1% pen/strep, and 
0.1% insulin-transferrin-selenium solution. Cells were lipid loaded overnight in 
serum free DMEM with 500 µM oleate, then pre-treated with 30 µM H89, a PKA 
inhibitor, for one hour before a ten minute treatment with 10 µM of a cell 
permeable cAMP analogue, 8-Bromoadenosine 3′,5′-cyclic monophosphate (8-
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Br-cAMP). Cells were fixed, stained for ACOT1, and DAPI and then mounted. 
COS7 cells were transfected using Effectene (Qiagen, Germantown, MD) 
transfection reagent with ACOT1-DsRed-Express. Cells were then treated and 
fixed as described for the AML12 studies.   
 
PPARα reporter assays. COS7 or L cells were transfected with PPARα reporter 
construct (pSG5-GAL4-Pparα), firefly luciferase reporter plasmid (DK-MH-
UASluc), control Renilla luciferase plasmid (pRLSV40), and empty DsRed-
Express N1 plasmid, Acot1-DsRed-Express N1, or Acot1-S232A-DsRed-Express 
N1. Cells were treated in serum free media with 500 µM oleate for 16 hours then 
treated with 8-Br-cAMP or vehicle for 6 hours before harvesting for assessment 
of reporter activity using the Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI). Firefly luciferase activity was normalized to Renilla luciferase 
activity.  
 
Thioesterase activity assay. Thioesterase activity was determined as 
previously described (26) with minor modifications. Frozen liver samples were 
homogenized with a dounce homogenizer for 15 seconds. Homogenates were 
centrifuged at 100,000xg at 4°C for 1 hour and supernatants were collected. 
Samples were diluted in assay buffer (50 mM KCl, 10 mM HEPES) and 1mg of 
protein was loaded per well. DTNB was added at a working concentration of 
50µM and read at 405nm at 37°C. Palmitoyl Co-A was added at 20 µM and read 
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at 405nm at 37°C for 3-5 minutes. CoA concentration was determined against a 
standard curve. Values were reported as nmoles CoA/min/mg protein.   
 
Liver and serum TG. For Tyloxapol studies, animals received an intraperitoneal 
injection of tyloxapol (200 mg/kg) after a 16 hour fast and facial vein samples 
were collected for analysis at 0, 1, 2, and 3 hours. Serum triglyceride (TG) was 
assessed using the Stanbio LiquiColor® Triglycerides No. 2100 (Stanbio 
Laboratory, Boerne, TX).   
 
Tissue FAs. Cellular FAs were determined by chloroform methanol extraction 
method. FA fraction was separated using thin layer chromatography and re-
suspended in chloroform. Samples were dried under nitrogen and FAs were 
converted to fatty acid methyl esters (FAME) by heating them to 90°C for 1 hour 
in 5% HCl-methanol. FAMEs were re-suspended in hexane and subjected to Gas 
Chromatography Mass Spectrometry with an internal C17:0 standard for total 
and species quantification. Nuclear preps were obtained from frozen liver tissue 
through homogenization in a nuclear lysis buffer containing 10 mM Tris-HCL, 10 
mM NaCl, 15 mM MgCl2, 250 mM sucrose, 0.5% NP-40, and 0.1 mM EGTA, pH 
7.5.  Lysates were separated through a 30% sucrose cushion (10 mM Tris-HCL, 
10 mM NaCl, 30% sucrose, 3 mM MgCl2) at 1300xg. Nuclear pellets were 
washed and a Bradford assay was used to quantify proteins. FAs were collected 
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via Dole extraction method. Samples were re-suspended in ethanol and 
quantified using the Wako HR Series NEFA-HR (2) kit.  
 
Pyruvate tolerance test. Eleven-week-old male mice received a tail vein 
injection of scramble control or Acot1 shRNA. One-week post transduction mice 
were fasted overnight and received an intraperitoneal injected of 2 g/kg of 
sodium pyruvate in sterile saline. Blood glucose was measured via a tail clip at 0, 
15, 30, 60, and 90 minutes.  
 
Glycogen. Liver glycogen was quantified by first digesting glycogen to glucose 
by boiling the sample in 2 M hydrochloric acid for five minutes. Samples were 
cooled and neutralized with 2 M NaOH. Glucose was then quantified via Wako 
AutoKit Glucose (Mount View, CA). 
 
Oxygen consumption rate. Seahorse XF analyzer was used to determine total 
oxygen consumption rate (OCR) in primary hepatocytes insolated from control 
and Acot1 knockdown mice after an overnight fast. Cells were seeded in a 
collagen coated XF cell culture plates at 3 x 104 cells/well and incubated at 37° 
for 4 hours to allow cells to attach. Media was changed to XF Assay media with 
5.5 mM glucose, 2 mM glutamax, and 1 mM pyruvate and placed in a CO2 
chamber for one hour. Basal oxygen consumption was measured for 30 minutes, 
followed by an injection of either BSA control or 500 µM of oleate and OCR was 
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determined for 30 minutes. Finally antimycin A was injected at 1 µM to determine 
non-mitochondrial oxygen consumption. Average basal OCR and OCR in 
response to BSA control or 500µM of oleate was calculated.  
 
Statistical Analysis. Values are expressed as the mean ± SEM. Statistical 
significance was determined by Student’s t-test.  
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Results 
ACOT1 is increased during fasting. To assess the expression pattern and 
cellular distribution of ACOT1, we harvested mice that were fed or fasted for 16 
hours. As expected, fasting resulted in a large induction of Acot1 mRNA (Fig. 
1A), which correlated to an increase in ACOT1 protein expression (Fig. 1B). 
Importantly, ACOT1 and ACOT2 are 93.7% homologues (27) and therefore the 
antibody generated for these studies recognizes both ACOT1 and ACOT2. 
However, ACOT2 is exclusively a mitochondrial protein (26) and previous groups 
have shown that ACOT2 runs below ACOT1 on Western blots (28). Therefore, to 
exhibit the specificity of our antibody, we compared our samples to those of 
mitochondrial preps from mouse liver overexpressing Acot2 (26). ACOT1 in liver 
lysates runs above ACOT2 as shown in Supplemental Fig. 1. ACOT2 is barely 
detectable in whole liver lysates compared to ACOT1. Consistent with the 
Western blot, ACOT1 exhibited low expression during the fed state but was 
robustly increased after 16 hours of fasting. As such, our studies primarily 
focused on mice in the fasted state when ACOT1 is expressed.  
ACOT1 has been described as a cytosolic protein, however to assess its 
cellular localization we stained liver sections for ACOT1. As expected, ACOT1 
was not present in the fed state, but was abundant during fasting. Although 
ACOT1 was largely cytosolic, we observed ACOT1 in the nucleus under fasted 
conditions (Fig. 1C), which was subsequently confirmed with Western blotting of 
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nuclear fractions (Fig. 1D), suggesting a potentially undocumented nuclear role 
of ACOT1. 
 
Figure 1. Hepatic ACOT1 is increased in fasting. C57Bl/6J mice were either 
fed or fasted overnight (16 hrs). (A) Acot1 expression was increased with fasting 
as analyzed by RT-PCR (n=5). (B) Western blot and densitometry of ACOT1 in 
fed and fasted mice. (C) Fixed liver sections from fed or fasted (16 hrs) mice 
were probed with the ACOT1 primary antibody and Alexa 488 secondary. (D) 
Western blots of nuclear preps from fed and fasted mice. *P<0.05. 
  52 
 
Supplemental Figure 1. ACOT1 antibody distinguishes between ACOT1 and 
ACOT2. (A) The ACOT1 antibody recognizes mouse ACOT1 and ACOT2. Liver 
homogenates from fed and 16 hour fasted mice were compared to mitochondrial 
preps from mice overexpressing Acot2.  
 
Acot1 knockdown reduces fasting liver TG by enhancing TG turnover 
and increases oxidation of endogenous and exogenous FAs.  To determine 
the contribution of ACOT1 to hepatic energy metabolism, we used adenoviral 
delivered shRNA to knockdown Acot1 in the liver. Seven days post transduction, 
control mice (cont. shRNA) or liver Acot1 knockdown mice (Acot1 shRNA) (n=7-
9) were fasted for 16 hours prior to sacrifice. We observed a significant reduction 
(~60%) in both Acot1 mRNA (Fig. 2A) and protein (Fig. 2B). 
Immunohistochemistry exhibited reduced cytosolic and nuclear ACOT1 with 
Acot1 knockdown (Fig. 2C). This reduction in ACOT1 expression correlated with 
reduced thioesterase activity (Fig. 2D).  
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Figure 2. Hepatic Acot1 knockdown reduces ACOT1 protein and 
thioesterase activity.  Acot1 expression is reduced in response to Acot1 
knockdown as analyzed by RT-PCR (A) and Western blotting of liver lysates (B) 
7 days post transduction (n=7-9). (C) Immunohistochemistry of ACOT1 from fix 
liver sections indicates reduced ACOT1 protein with Acot1 knockdown. (D) Acot1 
knockdown reduced thioesterase activity (n=3-4). *P<0.05. 
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Acot1 knockdown significantly reduced hepatic triglyceride content as 
determined by enzymatic assays and imaging of lipid droplets in H&E and Oil 
Red O stained liver sections (Fig. 3A-B). To confirm these effects were specific to 
the fasted state, we harvested control and Acot1 knockdown mice in the fed state 
when Acot1 is not expressed. As expected, there were no effects of Acot1 
knockdown on liver lipid droplet accumulation in fed mice consistent with its low 
expression in the fed state (Supplemental Fig. 2A).  These results suggest that 
ACOT1 predominantly regulates hepatic lipid metabolic pathways involved in 
fasting such as FA oxidation.  
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Figure 3.  Acot1 knockdown increases hepatic FA oxidation. (A) Acot1 
knockdown reduced hepatic TG. (B) H&E and Oil Red O stains of liver tissue 
show reduce lipid droplets in the Acot1 shRNA treatment group (n=7-9). (C) TG 
hydrolase activity was increased in liver tissue homogenates of mice treated with 
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Acot1 shRNA (n=4). (D) Serum β-hydroxybutyrate was increased following 
hepatic Acot1 knockdown in 16 hour fasted mice. (E) Acot1 knockdown did not 
influence [14C]oleate incorporation into cellular triglyceride (TG). (F) TG turnover 
as measured by [14C]TG loss during the chase period was increased in response 
to Acot1 knockdown.  Acot1 knockdown increased the oxidation of exogenous 
(G) and endogenous (H) FAs as measured by [14C]acid soluble metabolites 
(ASM) in the media (n=3).  
 
 
Supplemental Figure 2. Acot1 knockdown effects on hepatic lipid 
metabolism in the fed state. Control and Acot1 knockdown mice were 
harvested in the fed state. (A) Liver tissue were frozen in Tissue-Tek® O.C.T.  for 
H&E and Oil Red O staining. (B) Serum was assessed for β-hydroxybutyrate.  
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Although predominantly involved in fasting lipid metabolism, ACOT1 may 
be reducing hepatic TG through a reduction in de novo lipogenesis (DNL) and/or 
TG synthesis, enhanced TG secretion in the form of very-low density lipoprotein 
(VLDL), or enhanced TG breakdown and FA oxidation. Thus, we assessed each 
of these possibilities to confirm exactly which pathway(s) were altered leading to 
reduced hepatic TG content in response to Acot1 knockdown during fasting. To 
assess DNL and TG synthesis, we performed radiolabel experiments in primary 
hepatocytes isolated from mice transduced with scramble control or Acot1 
shRNA adenoviruses. We incubated cells for 2 hours with [14C]acetate or 
[3H]glycerol and measured incorporation of the label into the TG fraction. Rates 
of incorporation of either acetate or glycerol into the TG fraction were similar 
between treatment groups (Supplemental Fig. 3A-B) suggesting that DNL and 
TG synthesis are unaffected by Acot1 knockdown. Acot1 knockdown had little 
effect on serum TG (Supplemental Fig. 3C) or hepatic TG secretion based on 
serum TG from animals treated with tyloxapol (Supplemental Fig. 3D), 
suggesting no change in VLDL secretion. These results were confirmed with 
radiolabeling studies in primary hepatocytes, which showed that Acot1 
knockdown had no effect on secreted TG (Supplemental Fig. 3E). Together, 
these data suggest that changes in DNL, TG synthesis, or VLDL assembly and 
secretion are unaffected by Acot1 knockdown.   
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Supplemental Figure 3. Liver specific knockdown of Acot1 does not affect 
DNL, TG synthesis, or VLDL secretion. Pulse-chase experiments were 
conducted with [14C]glycerol, [14C]acetate, and [14C]oleate. Incorporation of 
[14C]acetate (A) and [14C]glycerol (B) into the triglyceride (TG) fraction after the 2 
hour pulse was similar between treatments. (C-D) Acot1 knockdown does not 
alter fasting serum TG (C) or changes in serum TG in response to tyloxapol to 
measure rates of VLDL secretion (D). Media [14C]TG after the 6 hour chase was 
similar between groups (E).   
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We next tested the effects of Acot1 knockdown on TG hydrolysis. There 
was a significant increase in TG hydrolase activity in tissue homogenates from 
livers treated with Acot1 shRNA compared to control livers (Fig. 3C). Enhanced 
lipolysis paralleled an increase in serum β-hydroxybutyrate (Fig. 3D) indicative of 
enhanced FA oxidation. We again confirmed these effects were specific to the 
fasted since Acot1 knockdown did not alter β-hydroxybutyrate in fed mice 
(Supplemental Fig. 2B). These data support a role for ACOT1 in mitigating the 
flux of acyl-CoAs to mitochondrial β-oxidation in the fasted state. To further 
assess alterations in FA flux, in vitro pulse-chase experiments were performed. 
Similar to the unchanged TG synthesis from acetate or glycerol (Supplemental 
Fig. 3A-B), incorporation of [14C]oleate into the cellular TG pool was similar 
between treatment groups (Fig. 3E). Consistent with increased TG hydrolysis in 
livers from Acot1 knockdown mice, turnover of [14C]TG was significantly greater 
with Acot1 knockdown in primary hepatocytes (Fig. 3F). Additionally, FA 
oxidation was significantly increased in both the pulse (Fig. 3G) and chase 
periods (Fig. 3H) in the Acot1 knockdown hepatocytes, suggesting there is an 
increase in oxidation of both endogenously produced and exogenously taken up 
FAs.  
We next assessed oxygen consumption rate (OCR) in primary 
hepatocytes from control and Acot1 knockdown mice using the Seahorse XF 
analyzer. As expected, Acot1 knockdown hepatocytes exhibited a significant 
increase in OCR with the addition of FAs compared to BSA control (Fig. 4A-B); 
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although basal rates were numerically higher they did not reach significance. 
These results support our findings that Acot1 knockdown increases oxidation of 
endogenous and exogenous FAs.  
 
Figure 4. Hepatic Acot1 knockdown increases oxygen consumption. 
Primary hepatocytes were isolated from control and Acot1 knockdown mice. 
OCR was determined in seahorse analyzer XF in the presence of (A) BSA 
control or (B) 500µM oleate.  
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To confirm the enzymatic importance of ACOT1 in regulating FA oxidation 
and TG turnover, we next transfected L cells with an empty DsRed-Express N1 
vector (EV), Acot1 DsRed-Express N1 (Acot1), or a catalytically dead mutant 
Acot1-S232A-DsRed-Express N1 (Acot1 S232A) and performed a pulse-chase 
with [14C]oleate. Expression and thioesterase activity of these mutants were 
confirmed in Supplemental Fig. 4. As expected, thioesterase activity was 
increased with Acot1 overexpression but was blunted with the Acot1 S232A 
mutant, confirming that the mutant was catalytically dead. These results were not 
due to differences in expression between the two mutants, apparent by the 
ACOT1 Western blot. Cells transfected with Acot1 exhibited less FA oxidation 
and more TG retention (Supplemental Fig. 5) compared the EV and Acot1 S232A 
mutant, indicating the catalytic activity of ACOT1 is necessary for its regulation of 
FA oxidation and TG turnover. Taken together, these data suggest that Acot1 
knockdown reduces hepatic TG levels through increased TG turnover and 
enhanced oxidation of both exogenous and endogenous FAs.  
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Supplemental Figure 4. Acot1 S232A ablates catalytic activity. Acot1-DsRed 
Express N1 (Acot1) and Acot1-S232A-DsRed Express N1 (Acot1 S232A) 
express similarly in COS7 cells (A) compared to the DsRed Express N1 (EV) yet 
Acot1-S232A has no thioesterase activity.  
 
Supplemental Figure 5. ACOT1 overexpression on lipid trafficking. L cells 
were transfected with Acot1-DsRed Express N1 (Acot1) and Acot1-S232A-
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DsRed Express N1 (Acot1 S232A) and treated with trace [14C]oleate along with 
500 µM unlabeled oleate bound to BSA (3:1 molar ratio) overnight, then chased 
for 6 hours with isotope free media. Compared to the DsRed Express N1 (EV), 
and catalytically dead mutant, Acot1-S232A-DsRed Express N1 (Acot1 S232A), 
Acot1-DsRed Express N1 (Acot1) had less (A) FA oxidation and greater (B) TG 
retention.  
 
ACOT1 regulates PPARα activity. Since there was an observed increase in FA 
oxidation, we next measured the expression of target genes of PPARα, the 
principal transcription factor governing hepatic FA oxidation (7), and peroxisome 
proliferator-activated receptor gamma co-activator (PGC1α), a co-activator of 
PPARα (29). Surprisingly, Acot1 knockdown reduced expression of PPARα and 
PGC1α target genes (Fig. 5A-B). In addition, catalase protein expression, a 
marker of peroxisome content, and mitochondrial DNA abundance were reduced 
with Acot1 knockdown (Fig. 5C-D). When combined with the aforementioned 
effects on FA oxidation, these results suggest that ACOT1 uncouples FA 
oxidation from the upregulation of genes and machinery involved in oxidative 
metabolism.  
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Figure 5. ACOT1 regulates expression of PPARα target genes, PGC1α 
target genes, and peroxisome and mitochondria abundance. Expression of 
(A) PPARα target genes and (B) PGC1α target genes were reduced with Acot1 
knockdown (n=7). (C) Catalase protein expression, a marker of peroxisome 
abundance, was reduced with Acot1 knockdown; densitometry represents n=5. 
(D) Mitochondrial DNA abundance was reduced with Acot1 knockdown. 
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We next speculated that the overexpression of ACOT1 could drive PPARα 
activity. To test this, COS7 cells and L cells were transfected with an EV, Acot1 
or Acot1-S232A plasmids and treated with vehicle or 8-Br-cAMP. The 
combination of 8-Br-cAMP and ACOT1 enhanced PPARα reporter activity more 
than 8-Br-cAMP alone in COS7 cells (Fig. 6A) and L cells (Fig. 6B). Moreover, 
induction of PPARα reporter activity by ACOT1 was dependent on its catalytic 
activity, suggesting that ACOT1 regulates PPARα through production of FA 
ligands.  
 
8-Br-cAMP promotes ACOT1 nuclear translocation. Although characterized 
as a cytosolic protein, the data in Fig. 1C-D and Fig. 2C, suggest that ACOT1 is 
also present in the nucleus. Since ACOT1 has no predicted nuclear localization 
sequence (30), yet has numerous putative PKA phosphorylation sites (31), we 
suspected that nuclear location of ACOT1 could be driven by elevated 
cAMP/PKA signaling during fasting. To test the translocation of ACOT1 under β-
adrenergic stimulation, AML12 cells were treated with H89, a PKA inhibitor, for 1 
hour followed by 8-Br-cAMP for an additional 10 minutes before cells were fixed 
and stained for ACOT1. Nuclear ACOT1 increased with the addition of 8-Br-
cAMP, however this effect was blocked by the PKA inhibitor H89 (Fig. 6C-D). 
Nuclear localization of ACOT1 was also confirmed in COS7 cells transfected with 
Acot1 DsRed-Express N1 treated with vehicle or 8-Br-cAMP (Fig. 6E). ACOT1 
signal was detectable in the nucleus in response to 8-Br-cAMP, but not when 
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treated with a vehicle. Previous groups have identified both FAs and acyl-CoAs 
in the nucleus (32), in which acyl-CoAs antagonize PPARα and FAs activate 
PPARα (33). In addition, saturated fatty acids have been shown to be 
endogenous to PPARα (34), while ACOT1 shows substrate preference toward 
saturated acyl-CoA species (9). These data suggest a link between ACOT1 
substrate and PPARα ligands. Combined with our previous data showing ACOT1 
catalytic activity is necessary for PPARα reporter activity (Fig. 6A-B), we 
speculate that nuclear ACOT1 regulates nuclear pools of saturated acyl-CoAs 
and free FAs to control PPARα activity during fasting. Surprisingly, we found no 
difference in cytosolic or nuclear free FAs with Acot1 knockdown (Supplemental 
Fig. 6). Free FAs are lipotoxic substances that are tightly regulated inside cells 
(1). It is possible that the ACOT1-derived FA pool may be too small or transient 
to see distinct differences in total quantity or that FAs are selectively channeled 
to influence PPARα activity. Primarily ACOT1 shows preference toward saturated 
acyl-CoAs (9), therefore activity may not change the entire nuclear pool of FAs, 
rather selectively increase the presence of free saturated FAs. 
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Figure 6. ACOT1 regulates PPARα activity and partially localizes to the 
nucleus. (A) COS7 and (B) L cells were transfected with an empty DsRed 
Express N1 (EV), Acot1-DsRed Express N1 (Acot1), or Acot1-S232A-DsRed 
Express N1, and reporter assay components (n=6-12). Cells were harvested and 
luciferase activity was assessed. ACOT1 translocated to the nucleus in AML12 
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cells in response to treatment with 8-Br-cAMP. Pretreatment with H89 blocked 
the translocation of ACOT1 in response to 8-Br-cAMP in (C) immunofluorescent 
staining and (D) nuclear fractionation and Western blotting. (E) An ACOT1 fusion 
construct (DsRed) showed partial nuclear localization in response to 8-Br-cAMP 
in COS7 cells. *P<0.05. 
 
Supplemental Figure 6. Hepatic Acot1 knockdown had no effect on hepatic 
FA content. (A) Total liver FAs were not changed with Acot1 knockdown as well 
as no significant change in abundance of (B) specific FA species. (C) Nuclear 
preps were isolated from liver tissue FAs were extracted via DOLE extraction 
method, and quantified.  
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ACOT1 is important for mitigating oxidative stress due to enhanced FA 
oxidation during fasting.  Enhanced FA oxidation can lead to the production of 
ROS in the electron transport chain leading to oxidative stress (35). In response 
to Acot1 knockdown, we observed enhanced FA oxidation (Fig. 3D) yet a 
reduction in oxidative machinery as indicated by reduced expression of PPARα 
targets (Fig. 5A-E). Such effects could lead to enhanced ROS generation and 
oxidative stress. Supportive of this logic, Acot1 knockdown livers exhibited 
significantly more ROS than the control livers (Fig.7A). In addition to increased 
ROS, Acot1 knockdown increased the expression of oxidative stress markers 
heme oxygenase 1 (Ho-1) and uncoupling protein 2 (Ucp2) (Fig. 7B). Increases 
in oxidative stress promotes inflammation (15) and PPARα is well-documented to 
be important for anti-inflammatory pathways (13,14). Thus, the reduction in 
PPARα targets along with increased oxidative stress suggests Acot1 knockdown 
could promote inflammation. Indeed, there was a significantly increase in 
expression of inflammatory markers Tnfα, Cd11c, Il-1β, and F4/80 (Fig. 7C). 
Consistent with enhanced inflammatory gene expression, Cd45 
immunohistochemistry revealed enhanced immune cell infiltration in livers with 
Acot1 knockdown (Fig. 7D). Similarly, immune cell infiltration can also be 
observed in the H&E micrographs (Fig. 3B). These results suggest that ACOT1 
mitigates oxidative stress and inflammation during fasting, potentially through 
enhancing PPARα activity.  
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Figure 7. Hepatic Acot1 knockdown increases inflammation and oxidative 
stress in mice. (A) Acot1 knockdown increased intracellular ROS measured by 
OxiSelect in vitro ROS/RNS Kit (n=4). (B) Acot1 knockdown increased 
expression of the oxidative stress genes heme oxygenase 1 (Ho-1) and 
uncoupling protein 2 (Ucp2). (C) Expression of inflammatory markers are 
increased in mice treated with Acot1 shRNA (n=7). (D) CD45 
immunohistochemistry stains from liver tissues revealed increased immune cell 
infiltration following Acot1 knockdown (n=2). *P<0.05. 
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The effects of Acot1 knockdown can be rescued by PPARα agonism. To 
further explore the potential role of ACOT1 in supplying FA ligands for PPARα 
activation, we attempted to rescue the effects of ACOT1 knockdown by feeding 
mice a diet supplemented with a synthetic PPARα ligand, Wy-14643. Mice were 
treated with adenovirus as described above and fed a purified control diet or a 
diet supplemented with 0.1% Wy-14643 (36) for one week. As expected Wy-
14643 significantly increased expression of ACOT1, however, Acot1 shRNA 
adenovirus significantly blunted this induction (Fig. 8A). Wy-14643 ablated the 
effects of Acot1 knockdown on reducing liver TG (Fig. 8B-C). However, Acot1 
knockdown and Wy-14643 independently and together increased TG hydrolase 
activity (Fig. 8D). As seen above, Acot1 knockdown increased serum β-
hydroxybutyrate in mice fed the control diet, while Wy-14643 significantly 
increased serum β-hydroxybutyrate to a similar level between treatment groups 
(Fig. 8E). Moreover, Wy-14643 rescued the expression of PPARα target genes in 
mice treated with Acot1 shRNA (Fig. 8F) as well as catalase protein expression 
(Fig. 8G). Since Wy-14643 is able to rescue the Acot1 knockdown phenotype, it 
is likely that ACOT1 is responsible for providing FA ligands for activation of 
PPARα.  
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Figure 8.  Wy-14643 rescues effects of Acot1 knockdown. (A) Acot1 mRNA 
following adenovirus treatments and 0.1% Wy-14643 supplementation (n=7-9). 
(B) H&E staining shows that Wy-14643 reduced and normalized lipid droplet 
accumulation in the Acot1 knockdown treatment group. (C) Wy-14643 
normalized liver TG levels between control and Acot1 shRNA treatment groups. 
(D) TG hydrolase activity and (E) serum β-hydroxybutyrate concentrations are 
increased and normalized following Wy-14643 in Acot1 shRNA treatment groups 
(n=4). (F) Wy-14643 increased PPARα target gene expression and rescued the 
effects of Acot1 knockdown. (G) Catalase protein expression is increased by Wy-
14643 and normalized in livers of Acot1 shRNA treated mice (n=2).  *P<0.05 vs. 
cont. shRNA group. #P<0.05 vs. control diet. 
 
We next explored the possibility that Wy-14643 could also rescue the 
oxidative stress and inflammation observed in response to Acot1 knockdown. 
Wy-14643 was able to normalize the expression of oxidative stress marker Ho-1, 
but was unable to normalize Ucp2 expression in Acot1 knockdown livers (Fig. 
9A).  Wy-14643 also normalized the expression of inflammatory genes and 
prevented immune cell infiltration in livers of Acot1 knockdown mice (Fig. 9B-C). 
In summary, these data suggest that ACOT1 regulates PPARα as a means to 
influence hepatic energy metabolism, oxidative stress, and inflammation.  
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Figure 9. Wy-14643 rescues inflammation and oxidative stress markers. (A-
B) Wy-14643 normalized the expression of most oxidative stress markers (A) and 
reduced the inflammatory markers observed with Acot1 knockdown (n=7-9) (B). 
(C) Wy-14643 normalized macrophage infiltration assessed by Cd45 
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immunohistochemistry staining (n=2). *P<0.05 vs. cont. shRNA group. #P<0.05 
vs. control diet. 
 
The effects of Acot1 knockdown in diet induced steatosis. NAFLD is a 
disease characterized by hepatic lipid accumulation. However, hepatic steatosis 
can then progress to inflammation and fibrosis (37). High fat diet feeding is 
known to cause steatosis in mice, however, it is unable to generate the fibrotic 
responses seen in NAFLD (38). Previously, we observed increased oxidative 
stress and inflammation in the absence of steatosis (Fig. 7). As such, we 
investigated the effects of Acot1 knockdown in mice fed a high fat diet, which 
should induce steatosis but not result in fibrosis. Mice were fed a 45% fat diet for 
12 weeks prior to an adenovirus delivery of cont. shRNA or Acot1 shRNA. One 
week later mice were fasted overnight (16 hrs) and sacrificed. As seen 
previously, Acot1 knockdown significantly decreased hepatic Acot1 expression 
(Fig. 10A) and ACOT1 protein (Fig. 10B). As expected, abundant lipid droplet 
accumulation was observed in livers of mice fed the high fat diet, but Acot1 
knockdown had similar hepatic TG content compared to controls (Fig. 10C-D). 
Acot1 knockdown increased serum β-hydroxybutyrate (Fig. 10E) despite 
unchanged expression of PPARα (Fig. 10F) or PGC1α (Fig. 10G) target genes.  
Despite the lack of reductions in gene expression, mitochondria content was 
reduced with Acot1 knockdown (Fig. 10H). Most importantly, Acot1 knockdown 
solicited a robust induction of inflammatory and oxidative stress markers (Fig. 
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10I), including α smooth muscle actin, a marker of fibrosis. Acot1 knockdown 
also increased hepatic ROS/RNS species (Fig. 10J) and greater Sirius Red 
staining, a marker of fibrosis (Fig. 10K). Together these data suggest that under 
high fat diet induced steatosis, ACOT1 is protective against inflammation and 
oxidative stress that leads to fibrosis.   
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Figure 10. Hepatic Acot1 knockdown exacerbates complications on a high 
fat diet.  Acot1 expression is reduced as measured by (A) Western blotting and 
(B) RT-PCR (n=8-10). Acot1 knockdown had no effect on hepatic TG (C) H&E 
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and (D) liver TG quantification. (E) Acot1 knockdown increased serum β-
hydroxybutyrate. Acot1 knockdown had no effect on (F) PPARα and (G) PGC1α 
target gene expression, yet significantly reduced total (H) mitochondrial 
abundance. (I) Acot1 knockdown increased expression of inflammatory and 
oxidative stress genes. (J) Acot1 knockdown increased intracellular ROS 
measured by OxiSelect in vitro ROS/RNS Kit (n=4). (K) Sirius Red staining 
indicated more fibrosis with Acot1 knockdown.  
 
ACOT1 regulates hepatic glucose metabolism. Since we observed a 
significant increase in hepatic FA oxidation and ketone production (Fig. 3), we 
speculated that Acot1 knockdown might have an impact on fasting glucose 
storage and production. FA oxidation is the primary energy provider for hepatic 
gluconeogenesis (20). As such, previous groups have demonstrated that FA 
oxidation can drive hepatic gluconeogenesis (21). To test if hepatic FA oxidation 
could drive gluconeogenesis we assessed fasting serum glucose levels and 
found that Acot1 knockdown significantly increased fasting glucose (Fig. 11A) 
We next performed a pyruvate tolerance test to assess gluconeogenesis in 16 
hour fasted control and Acot1 knockdown mice. There was a significant increase 
in glucose production in response to Acot1 knockdown (Fig.11B-C). Together 
these results suggest that Acot1 knockdown results in enhanced fasting 
gluconeogenesis. 
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Interestingly, hepatic glycogen was also robustly upregulated in Acot1 
knockdown mice (Fig. 11D-E). PPARα has been shown to increase 
glycogenolysis and rats fed a synthetic PPARα ligand exhibited depleted 
glycogen stores (39), however, the mechanism by which PPARα regulates 
hepatic glycogen synthesis or degradation is not well understood. Since Wy-
14643 was able to normalize FA oxidation and PPARα target genes in Acot1 
knockdown mice (Fig. 8), we speculated that hepatic glucose metabolism would 
also be normalized. As expected, Wy-14643 reduced hepatic glycogen stores 
compared to control, but did not reach significance. Wy-14643 also normalized 
hepatic glycogen stores between control and Acot1 knockdown mice (Fig. 12A-
B). These results suggest hepatic glycogen stores seen with Acot1 knockdown 
were due to reduced PPARα signaling.  
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Figure 11. Acot1 knockdown increases hepatic glycogen storage. (A) 
Fasting serum glucose was greater in Acot1 knockdown mice. (B-C) Acot1 
knockdown slightly increased hepatic glucose production during a pyruvate 
tolerance test. (D) Periodic-Acid Schiff (PAS) and PAS with diastase (PAS-D) 
stains indicated greater glycogen storage in Acot1 knockdown mice. (E) Hepatic 
glycogen was quantified by digesting glycogen and subsequently measuring 
glucose.  
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Figure 12. Wy-14643 normalized hepatic glucose metabolism. Wy-14643 
normalized hepatic glycogen stores in Acot1 knockdown measured by (A) 
PAS/PAS-D stains and (B) glycogen quantification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  82 
Discussion 
The liver imports FAs proportional to their concentration in the blood. Thus, 
increased rates of FA metabolism must match this uptake during times of fasting. 
Upon entering the liver, hepatic FAs are first converted to acyl-CoA molecules 
prior to their entry into most metabolic pathways (3). ACOT1 catalyzes the 
reverse reaction, producing free FAs (5), which should slow the flux of FAs to 
downstream metabolic pathways. Consistent with this logic, hepatic knockdown 
of Acot1 increased the oxidation of FAs in vivo and in vitro (Fig. 3), while having 
no observed effect on TG synthesis or VLDL secretion (Supplemental Fig. 3). 
Taken together, these results suggest that ACOT1 specifically regulates FAs 
destined to oxidative pathways, potentially by removing acyl-CoAs as substrates. 
By slowing FA oxidation, ACOT1 may serve to protect the liver from detrimental 
effects of excessive FA oxidation. 
PPARα is a dominant transcription factor in the liver, responsible for the 
upregulation of genes involved in FA oxidation during fasting (7,40). Acot1 
knockdown led to enhanced FA oxidation, which would be expected to correlate 
to greater expression of several PPARα target genes. However, PPARα targets 
were reduced (Fig. 4A) following Acot1 knockdown despite the greater oxidative 
rate. Since FAs serve as endogenous ligands to activate PPARα (10), we 
speculated that ACOT1 provides FA ligands to activate PPARα. Therefore, 
administration of a synthetic PPARα ligand (e.g.Wy-14643) should rescue the 
effects of hepatic Acot1 knockdown on PPARα signaling. Wy-14643 treatment 
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largely rescued the phenotype resulting from ACOT1 knockdown including 
normalization of FA oxidation and PPARα target genes (Fig. 8). We also tested if 
ACOT1 thioesterase activity was necessary for its regulation of PPARα. 
Expressing ACOT1 in COS7 or L cells increased PPARα reporter activity during 
8-Br-cAMP stimulation. However, a catalytically dead ACOT1 mutant (Acot1 
S232A) had no effect on PPARα activity compared to the empty vector control 
(EV) (Fig. 6A-B), supporting the theory that ACOT1 thioesterase activity provides 
FA ligands to regulate PPARα. However, we found no difference in cellular FAs 
(Supplemental Fig. 6). As such, we surmise that ACOT1 specifically produces a 
local small pool of FAs to activate PPARα. Further studies are needed to 
determine if ACOT1 and PPARα interact, which would suggest ACOT1 hands FA 
ligands directly to PPARα.  
ACOT1 overexpression alone was not sufficient to increase PPARα 
reporter activity, only during cAMP/PKA signaling did ACOT1 solicit PPARα 
activation (Fig. 6A-B). We observed nuclear localization of ACOT1 in response to 
8-Br-cAMP (Fig. 6C-E), suggesting nuclear localization may be necessary for 
ACOT1 to activate PPARα. Similarly, Acot1 knockdown reduced nuclear ACOT1 
(Fig. 2C) and subsequently reduced PPARα transcripts (Fig. 5A). Thus, these 
data show that ACOT1 produces FA ligands to activate PPARα, increasing FA 
oxidative capacity. This regulation may be dependent on the nuclear localization 
of ACOT1 in response to fasting and cAMP/PKA signaling. 
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Normal mitochondrial oxidation produces a mild stress on cells resulting in 
the production of ROS (15). However, ROS production is balanced by 
mitochondrial antioxidant activity that protects the mitochondria from oxidative 
stress. During times of increased FA oxidation, ROS can exceed antioxidant 
capacity and lead to oxidative stress (41). In addition, PPARα signaling limits 
oxidative stress (42,43) and promotes the expression of anti-inflammatory genes 
(13). There was greater hepatic ROS and expression of oxidative stress markers 
in hepatic Acot1 knockdown mice (Fig. 5A-B) that paralleled elevated rates of FA 
oxidation (Fig. 3) and reduced PPARα target gene expression (Fig. 5A). 
Additionally, there was greater expression of inflammatory genes and immune 
cell infiltration in response to Acot1 knockdown (Fig. 7C-D). Thus, the observed 
inflammation in response to Acot1 knockdown could be due to reduced PPARα 
dependent anti-inflammatory gene expression. Wy-14643 treatment rescued the 
oxidative stress and inflammation seen in Acot1 knockdown livers (Fig. 9). As 
such, ACOT1 appears to protect the liver from oxidative stress and inflammation 
via promotion of PPARα signaling.  
NAFLD is an inclusive title for a spectrum of liver disease states that 
includes steatosis, nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis 
(37). NAFLD is initially characterized by lipid droplet accumulation, followed by 
enhanced oxidative stress and inflammation that progresses the disease to 
NASH. Since Acot1 knockdown had a significant impact on hepatic oxidative 
stress and inflammation in mice on a control diet potentially due to greater 
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oxidative metabolism, we speculated that Acot1 knockdown could progress high 
fat diet induced hepatic steatosis to a fibrotic state. Unlike under basal 
conditions, weeklong Acot1 knockdown did not significantly reduce hepatic TG, 
yet increased serum β-hydroxybutyrate. Acot1 knockdown did not solicit the 
same effects on PPARα and PGC1α as seen in mice fed the control diet, but 
increased oxidative stress and inflammation ultimately leading to fibrosis. Current 
evidence suggests that high fat diets increases FA oxidation (44) which 
correlates with the increase in serum β-hydroxybutyrate we see in mice fed a 
high fat diet (Fig. 10E) compared to basal mice (Fig. 3D). This increase in FA 
oxidation is associated with the oxidative stress and inflammation that occurs as 
the disease progresses (45). Our findings support the importance of FA oxidation 
and its complications in the progression of NAFLD from steatosis to fibrosis.  
Lastly, we investigated the role of FA oxidation on glucose homeostasis 
during prolonged fasting with Acot1 knockdown. Hepatic FAs can inhibit 
glycogenolysis and FA oxidation can increase gluconeogenesis (21,37,46). As 
expected, Acot1 knockdown resulted in greater glucose production and glycogen 
storage after a 16 hour fast (Fig. 11). Normally after a 16 hour fast glycogen is 
depleted by ~80% (47). Therefore these results suggest that Acot1 knockdown 
causes FA oxidation that promotes gluconeogenesis and conserves hepatic 
glycogen stores.  
To our knowledge, these are the first studies to characterize the 
physiological importance of ACOT1 in hepatic fasting lipid metabolism. This 
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study highlights a significant role for ACOT1 in regulating FA oxidation, PPARα 
activity, oxidative stress, and inflammation during fasting. In support of a 
protective role of ACOT1, humans with fewer copy numbers of the 14q24.3 locus 
where ACOT1 resides are more likely to develop NASH, a disease in which 
oxidative stress and inflammation are the defining characteristics (48). Similarly, 
overexpression of ACOT1 improves diabetic cardiomyopathy by reducing FA 
oxidation and ROS production (19). Thus, when combined, the few studies 
evaluating ACOT1 all highlight a potential beneficial role of ACOT1 in mitigating 
the negative effects of aberrant lipid metabolism. 
Based on our current findings, ACOT1 plays a pivotal role in protecting 
livers by regulating FA oxidation and the ensuing oxidative stress and 
inflammation while simultaneously promoting PPARα activity (Fig. 13). In 
addition, ACOT1 locates to the nucleus during fasting, suggesting a potential 
local regulation of PPARα via the production of FA ligands. Thus, this work 
highlights the importance of ACOT1 as a branch point in regulating FA flux to 
oxidative pathways and controlling the transcriptional regulation of FA oxidation.  
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Figure 13.  Proposed mechanism of ACOT1 in fasting liver lipid 
metabolism. ACOT1 expression during fasting mitigates FA flux toward 
oxidation in the cytosol. Under fasting and elevated cAMP/PKA stimulation, 
nuclear ACOT1 is important in the activation of PPARα. Fasting with reduced 
ACOT1 enhances FA oxidation with reduced PPARα activity that leads to 
oxidative stress and inflammation. Therefore, ACOT1 is an important enzyme for 
balancing oxidative capacity, oxidative stress, and inflammation with PPARα 
activity during fasting.  
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Chapter 3 
 
 
 
 
 
Whole-Body Acot1 Knockout Protects 
From Adiposity and Hepatic Steatosis 
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Acyl-CoA thioesterase 1 (ACOT1) catalyzes the hydrolysis of long chain acyl-
CoAs to free fatty acids (FAs) and coenzyme A. ACOT1 is expressed 
predominantly in oxidative tissues such as liver, heart, and kidney during times of 
enhanced oxidative needs, such as fasting or exercise. The physiological 
relevance of ACOT1 in these tissues is poorly understood. We previously 
demonstrated that acute hepatic Acot1 knockdown significantly reduced hepatic 
triglyceride (TG), enhanced gluconeogenesis, and resulted in oxidative stress 
and inflammation. Therefore, this study sought to determine the effects of whole-
body Acot1 knockout in mice fed a purified control diet (control) or a 45% fat diet 
(HFD) for 12 weeks. Acot1 knockout protected from diet induced obesity in male 
and female mice. Acot1 knockout reduced adipocyte size, but increased the 
number of adipocytes, suggesting greater hyperplasia and less hypertrophy. 
However, discrepancies in weight gain were not accounted for by changes in 
energy expenditure, locomotion, or food intake. Acot1 knockout also reduced 
hepatic lipid accumulation during fasting and protected mice from HFD induced 
steatosis. Reduced hepatic TG correlated to a reduction in hepatic reactive 
oxygen species (ROS). However, an oral glucose tolerance test (OGTT) revealed 
impaired glucose tolerance in Acot1 knockout mice. In conclusion, these studies 
suggest that Acot1 is physiologically relevant in adiposity and ectopic lipid 
accumulation in basal conditions and in response to high fat feeding.  
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Introduction 
Dietary fat, de novo lipogenesis (DNL), and reduced FA oxidation contribute to 
increased lipid storage, a defining feature of obesity and the metabolic syndrome 
(1). Increased adiposity leads to ectopic lipid accumulation in tissues such as 
liver, heart, and muscle. (2). Hepatic TG accumulation is the initial characteristic 
of non-alcoholic fatty liver disease (NAFLD). Progressive states of NAFLD are 
defined by increased oxidative stress, inflammation, and impaired mitochondrial 
function (3). In addition, the development of NAFLD is strongly correlated to the 
risk of insulin resistance (4). Although TG accumulation itself is not considered 
harmful, numerous lipid intermediates act as signaling molecules that contribute 
to the pathophysiology of ectopic lipid accumulation (5). As such, understanding 
the regulation of lipid channeling and signaling may explain the mechanism by 
which ectopic lipid leads to inflammation and insulin resistance.  
A family of acyl-CoA synthetases generate acyl-CoA molecules from free 
FAs and coenzyme A (6). Acyl-CoAs are then substrates for many metabolic 
pathways including FA oxidation or synthesis of complex lipid species including 
TG (7). A family of acyl-CoA thioesterases are responsible for cleaving acyl-CoA 
molecules back to free FAs (8). These acyl-CoA thioesterases are believed to 
serve as regulator enzymes, maintaining the level of acyl-CoAs and free FAs (8–
11). In particular, ACOT1 is the primary cytosolic thioesterase found in oxidative 
tissue, including the heart, liver, kidney, and muscle. ACOT1 responds to 
circadian cues including feeding and fasting, exercise, and light and dark cycles 
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(12–14). ACOT1 predominately cleaves long chain acyl-CoA molecules (15,16), 
rendering it an important enzyme for regulating the concentration and metabolic 
fate of both fatty acids and long chain acyl-CoAs.  
We previously described the effects of acute Acot1 knockdown in the liver. 
Acot1 knockdown resulted in enhanced FA oxidation and reduced peroxisome 
proliferator-activated receptor α (PPARα) target gene expression. This 
combination led to increased oxidative stress and inflammation, a phenotype 
typical in advanced stages of NAFLD (17,18). These results suggest that ACOT1 
may play a beneficial role in attenuating oxidative stress and inflammation. 
Therefore, we sought to determine the metabolic effects of chronic global whole-
body Acot1 ablation.  
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Research Design and Methods 
Mouse handling. All protocols were approved by the Institutional Animal Care 
and Use Committee of the University of Minnesota. ACOT1 heterozygous mice 
were purchased from the NIH knockout mouse project. Heterozygous mice were 
bred and offspring were genotyped at 3 weeks of age to identify wild type (WT) 
and knockout (KO) littermates. DNA was isolated from tail clips using DNeasy 
blood and tissue kit from Qiagen (Germantown, MD) and genotyped based on 
PCR protocols provided by the NIH knockout mouse project. Primers to identify 
the gene and cassette were used to genotype litters. Mice were housed in a 
controlled temperature (20°-22°C) and light (14 hrs light/10 hrs dark) vivarium 
with free access to water. At 8 weeks of age, WT and KO male and female mice 
were fed a purified diet (TD.94045; control) or a 45% fat diet (TD.06415; HFD) 
from Harlan Teklad (Madison, WI) for 12 weeks.  Mice were fasted overnight (16 
hrs) prior to sacrifice.  
 
Metabolic chambers. Male mice fed a control or HFD for ten weeks were 
transferred to the metabolic core facility one week prior to study initiation to adapt 
to the environment. Oxygen consumption (VO2), and carbon dioxide production 
(VCO2) were measured via Oxymax Comprehensive Lab Animal Monitoring 
System by (Columbus Instruments, Columbus, OH) for 24 hours in the fed ad 
libitum state and 24 hours in the fasted state. Respiratory exchange ratio (RER) 
and energy expenditure (kcals/h) were generated from formulas provided by the 
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manufacturer. VO2, VCO2, and energy expenditure are presented as estimated 
marginal means after an ANCOVA analysis with body weight as the covariate 
(19). Statistical analysis was determined with post-hoc Tukey test.  
 
TG and serum analyses. Hepatic TG was determined via chloroform:methanol 
extraction method. Hepatic TG and serum TG were quantified using the the 
Stanbio LiquiColor® Triglycerides No. 2100 assay (Stanbio Laboratory, Boerne, 
TX). Serum NEFAs were determined with a Wako HR Series NEFA-HR (2) kit. 
Serum β-hydroxybutyrate was assessed using a β-hydroxybutyrate LiquiColor Kit 
(Stanbio Laboratory, Boerne, TX).  
 
RNA isolation and analyses.  mRNA abundance was determined via RNA 
isolation using the Trizol Reagent (ThermoFisher, Waltham, MA). cDNA was 
made using SuperScript®VILO (Invitrogen, Carlsbad, CA) and SYBER Select 
(ThermoFisher, Waltham, MA) was used to quantitative mRNA abundance via 
RT-PCR.  
 
Protein preparation and Western blotting. Protein was isolated from tissues 
via homogenization and sonication in lysis buffer. Protein concentration was 
quantified by BCA. ACOT1 abundance and knockout was determined by 
Western blot with a custom antibody described in chapter two. 
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ROS determination. Cellular hepatic ROS was determined using the OxiSelect 
In Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc., San Diego, CA). Samples were 
measured at 480 nm excitation and 530 nm emission and compared to a 
standard curve.  
 
Oral glucose tolerance test. Glucose tolerance was assessed at ten weeks on 
diet, after an overnight fast (16 hrs). Blood glucose was taken at baseline from a 
tail clip, and then take 15, 30, 60, and 90 minutes after an oral gavage of 20% 
dextrose solution (2g/kg body weight).  
 
Tissue imaging.  Tissue sections were fixed in 10% formalin and subsequently 
paraffin embedded or cryosections were made by submerging samples in Tissue 
Tek ® O.C.T. Compound from Sakura Finetek (Torrance, CA) and freezing in 
isopentane. Slides were deparaffinized and blocked in 3% BSA, incubated with 
ACOT1 antibody overnight, stained with DAPI, and mounted. Oil red O and H&E 
stains were generated from the University of Minnesota’s BioNet Histology and 
IHC Lab.  
 
Thioesterase activity assay. Thioesterase activity was determined in male mice 
fed a purified diet. Frozen liver samples were homogenized and centrifuged 
100,000g at 4°C for 1 hour and supernatants were collected. One mg of protein 
was added per well in assay buffer (50 mM KCl, 10 mM HEPES). DTNB was 
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added at a working concentration of 50 µM and read at 405nm at 37°C. Palmitoyl 
Co-A was added at 20 µM and read at 405nm at 37°C for 3-5 minutes. CoA 
concentration was determined against a standard curve. Values are reported as 
nmoles CoA/min/mg protein.   
 
Statistical analysis. Values are expressed as the mean ± SEM. Statistical 
significance was determined by student t-tests or two-way ANOVA tests with 
Post-hoc student’s t-test where appropriate. Statistical significance for the 
metabolic cage data was determined as described above.  
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Results 
A high fat diet differentially regulates Acot1 expression in tissues. Previous 
groups have demonstrated that Acot1 mRNA is increased after 12 weeks on a 
HFD in liver, heart, kidney, and muscle, and ACOT1 protein is increased in liver 
and heart (10). We assessed the expression of Acot1 as well as ACOT1 protein 
in liver, heart, kidney, and muscle of our WT mice fed a control or HFD for 12 
weeks (Supplemental Fig. 1A-B). Acot1 mRNA abundance was increased in 
heart and muscle, however there was no change in the kidney and a reduction in 
Acot1 expression in liver in response to the HFD. ACOT1 protein was 
upregulated in mice fed a HFD in liver, heart, and kidney, but was undetectable 
in muscle. The discrepancy between Acot1 expression and ACOT1 protein in 
liver and kidney suggest that the protein increase may be driven by changes in 
ACOT1 degradation or posttranscriptional mechanisms rather than transcription.  
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Supplemental Figure 1. ACOT1 in control and HFD. (A) Acot1 expression and 
(B) ACOT1 protein in oxidative tissues from male mice fed a control or HFD for 
12 weeks.  
 
Generation of Acot1 knockout mice. To investigate the physiological role of 
ACOT1, Acot1 knockout mice (VG12838) were purchased from the NIH knockout 
mouse project. The mice were generated via a deletion in Chromosome 12 
where Acot1 resides, deleting 7,874 base pairs that were replaced with a 6,084 
base pair ZEN-Ub1 cassette (Fig. 1A). Littermates from Acot1 heterozygous 
breeding pairs were genotyped using primer sets to identify Acot1 DNA as well 
as the presence of the cassette (Fig. 1B). ACOT2 is a mitochondrial thioesterase 
and shares 93.7% homology to ACOT1 (20), and runs slightly below ACOT1 in 
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SDS-PAGE gels (21). We confirmed ACOT1 knockout and assessed ACOT2 
compensation by Western blotting (Fig. 1C) as well as RT-PCR (Fig. 1D). Acot1 
knockout was confirmed in oxidative tissues, liver, heart, and kidney in male mice 
fed a control diet for three months prior to being fasted overnight (Fig. 1C). Liver 
and kidney had more ACOT1 protein compared to the heart. As such, the heart 
seems to express more ACOT2 than ACOT1 especially with Acot1 knockout (Fig. 
1C-D). Lastly, we measured acyl-CoA thioesterase activity in WT and KO livers 
of male mice. As expected, KO mice had less thioesterase activity than their WT 
littermates (Fig. 1E). However total thioesterase activity wasn’t ablated, likely due 
to the presence of other cytosolic thioesterases such as ACOT7 (22). 
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Figure 1. Acot1 knockout. C57Bl/6J mice were genotyped at 3 weeks of age 
following exposure to purified diet for 3 months and an overnight (16 hrs) fast. (A) 
Genotyping schematic from the NIH KOMP. (B) Example gel electrophoresis 
results from genotyped samples. (C) ACOT1/ACOT2 protein (D) and mRNA 
abundance of Acot1 and Acot2 were assessed in oxidative tissue of WT and KO 
male mice fed a control diet. (E) Hepatic thioesterase activity was assessed 
between WT and KO male mice.  *P<0.05 vs. WT.  
 
Acot1 knockout protects from diet-induced adiposity. Male and female WT 
and KO mice on either a control or HFD were weighed weekly for 12 weeks. 
Male KO mice exhibited significantly lower weights at the beginning of the study 
and continued to be lighter than WT mice throughout the study (Figure 2A,C) 
regardless of diet. Unlike the males, female mice started at similar weights, yet 
female KO mice on a HFD gained significantly less weight compared to the WT 
controls (Figure 2B,C). We next assessed adipose depot weights. Male KO mice 
fed a HFD had similar epididymal adipose depots (Fig. 2D), but reduced inguinal 
adipose compared to WT controls (Fig. 2E). Female KO mice fed a HFD had 
significant reductions in both epididymal (Fig. 2D) and inguinal (Fig. 2E) adipose 
tissue. These results are supported by studies that suggest males are prone to 
inguinal adiposity while females gain fat in both inguinal and epididymal depots 
(23). Together, these data suggest that Acot1 knockout protects male and female 
mice from diet-induced adiposity.  
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Figure 2. Acot1 knockout effected body weight and adiposity. (A) Male and 
(B) female WT and Acot1 KO mice were weighed every week for the 12 week 
study and average (C) percent weight gain was calculated from week 0 to week 
12. (D) Epididymal and (E) inguinal tissue weights in male and female WT and 
KO mice fed a control or HFD and fasted overnight. *P<0.05 vs. WT. #P<0.05 vs. 
control diet. 
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Acot1 knockout reduces adiposity.  Recent studies suggest that ACOT1 is 
important in lipid accumulation during differentiation of pre-adipocytes to 
adipocytes (24). As such reduced adiposity may be driven by impaired 
maturation of adipocytes, reducing their storage capacity. DEXA scans confirm 
that male KO mice indeed had reduced body fat when fed a control or HFD (Fig. 
3A). To investigate adiposity further, we fixed tissue from both epididymal and 
inguinal adipose depots for H&E staining (Fig. 3B). Surprisingly, KO mice 
exhibited smaller adipocyte size (Fig. 3C) and more adipocytes (Fig. 3D). These 
results suggest that KO mice have reduced hypertrophy, supporting the theory 
that ACOT1 promotes lipid storage. Next, we measured inflammatory gene 
expression in inguinal adipose tissue (Fig. 3E). There was a reduction in 
inflammatory markers in KO mice fed a HFD, but there was no difference in 
macrophage recruitment as measured by F4/80 and Cd11c expression. Together 
these data suggest that Acot1 knockout reduces adipocyte size and increases 
adipocyte number, and protects adipocytes from inflammation.   
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Figure 3. Acot1 knockout reduced adiposity. (A) DEXA scans of male WT and 
KO mice. (B) H&E stains from male WT and KO mice. Acot1 knockout results in 
(C) smaller adipocytes in both control and HFD dietary conditions as well as (D) 
more adipocytes in epididymal and inguinal adipose depots. (E) Inflammatory 
markers in inguinal adipose tissue.  
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Acot1 knockout has no effect on whole-body energy metabolism. 
To determine if global Acot1 ablation affects whole-body energetics we subjected 
male WT and KO mice fed a control or HFD for 10 weeks to metabolic chambers. 
Since Acot1 expression is regulated by nutritional state (13), mice were 
examined for 24 hours in the fed state and 24 hours in the fasted state. There 
was no significant difference in VO2 (Fig. 4A-C) and VCO2 (Fig. 4D-F) for WT and 
KO male mice on a control or HFD. We next assessed respiratory exchange 
ratios (RER) to determine substrate oxidation. As expected HFD significantly 
lowered RER in the light and dark phases in the fed state, and in the light phase 
during fasting, suggesting greater lipid utilization (Fig. 5A-C). However, there was 
no significant difference between WT and KO mice. There was no significant 
difference in energy expenditure, however, KO mice fed a HFD were trending 
toward greater energy expenditure in the dark cycle (Fig. 5D-F). Consistent with 
unaltered energy expenditure, there were also no differences in locomotion 
between WT and KO mice on either diet (Supplemental Fig. 2). In addition, food 
intake could not account for the discrepancy in weight and adiposity in WT and 
KO mice (Supplemental Fig. 3). These results do not identify a clear mechanism 
by which Acot1 knockout reduces adiposity. We observed a significant 
discrepancy in weight of male mice at the start of the study, suggesting that 
ACOT1 may be important in pre- and post-natal development leading to impaired 
lipid utilization and storage at least in males (24).  
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Figure 4. Indirect calorimetry of male WT and KO mice. (A-C) Oxygen 
consumption rate (VO2) and (D-F) carbon dioxide production (VCO2) of WT and 
KO males fed a control (A,D) or HFD (B,E) for 10 weeks (n=3-4). Average (C) 
VO2 and (F) VCO2 during the night (10 hrs dark cycle) and day (14 hrs light 
cycle) in fed (24 hrs) and fasted (24 hrs) conditions. All values are represented 
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as estimated marginal means generated from an ANCOVA analysis with body 
weight as the covariate. Statistics were determined via Tukey Post-hoc test. 
 
Figure 5.  Respiratory exchange ratio and energy expenditure in male WT 
and KO mice. (A-C) Respiratory energy ratio (RER) and (D-F) energy 
expenditure for WT and KO mice fed a control (A,D) or a HFD (B,E) for 10 
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weeks. (n=3-4). Average RER (C) and energy expenditure (F) during the night 
(10 hrs dark cycle) and day (14 hrs light cycle) in fed (24 hrs) and fasted (24 hrs) 
conditions. Energy expenditure is represented as estimated marginal means 
generated from an ANCOVA analysis with body weight as the covariate. 
Statistics were determined via Tukey Post-hoc test. 
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Supplemental Figure 2. Locomotion of WT and KO male mice on control 
and HFD. (A-C) Ambulatory movement was recorded for 48 hours during which 
mice were either in fed state or were fasted.  
 
Supplemental Figure 3. Food intake in male and female mice. Average food 
intake was determined under control or HFD conditions.  
 
Acot1 knockout does not alter fasting serum glucose but impairs glucose 
tolerance. Previously we reported that hepatic Acot1 knockdown enhances 
gluconeogenesis and greater glycogen stores under fasting conditions. To 
assess if chronic Acot1 knockout would elicit a similar effect, we measured 
fasting glucose in male and female mice. As expected, HFD increase fasting 
glucose in both male and female mice (Fig. 6A). However, Acot1 knockout did 
not further increase fasting glucose but rather reduced fasting glucose in female 
KO mice on a HFD. We next assessed glycogen stores via Periodic acid-Schiff 
stain with and without diastase. There was no significant difference in fasting 
glycogen stores between WT and KO mice (Fig. 6B). These results suggest that 
Acot1 knockout had no effect on fasting hepatic glucose homeostasis.  
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Figure 6. Acot1 knockout mice exhibit normal glucose metabolism during 
fasting. (A) Fasting serum glucose was measured in male and female mice. (B) 
Periodic-Acid Schiff Staining (PAS) and Periodic-Acid Schiff staining with 
diastase (PAS-D) were performed on fixed liver sections to assess hepatic 
glycogen stores.  
 
Since we saw significant differences in body weight and adiposity (Fig. 2) 
between WT and KO mice, we next investigated glucose tolerance via an oral 
glucose tolerance test. Ten weeks after dietary interventions, mice were fasted 
for 16 hours then received an oral gavage of glucose (2 g/kg). Male KO mice had 
  114 
impaired glucose clearance compared to WT in response to both control and 
HFD (Fig. 7A,C), whereas female KO mice had impaired glucose clearance only 
under HFD conditions (Fig. 7B,C). HFD resulted in higher serum insulin, yet there 
was no significant difference between WT and KO mice (Fig. 7D). Together these 
results suggest that Acot1 knockout has no effect on fasting glucose production 
but impairs glucose tolerance during feeding.  
 
Figure 7. Acot1 knockout disrupts glucose tolerance. OGTTs were 
performed on (A) male and (B) female mice on a control and HFD for 10 weeks 
prior to an overnight fast (16 hrs) (n=4-7). (C) Acot1 knockout reduced glucose 
clearance after an OGTT as evident by iAUC. (D) Fasting serum insulin was in 
male and female mice. *P<0.05 vs. WT. #P<0.05 vs. control diet. 
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Acot1 knockout reduces fasting liver TG and protects from HFD induced 
steatosis. Because Acot1 is highly expressed in the fasted liver, we assessed 
the effects of whole-body Acot1 knockout on hepatic lipid homeostasis after a 16 
hour fast. There was no significant difference in liver weight between any of the 
groups (Fig. 8A). However, KO mice exhibited significant reduction in hepatic TG 
seen in H&E and Oil Red O staining (Fig. 8B) as well as chemical analysis (Fig. 
8C). Hepatic TG content during fasting is influenced by many factors including 
rate of oxidation, flux of non-esterified fatty acids (NEFAs) coming from adipose 
tissue, and secretion of very low-density lipoproteins (VLDL). There was a 
significant increase in serum β-hydroxybutyrate, indicative of increased FA 
oxidation in KO males on a HFD compared to WT, an effect that was absent in 
females (Fig. 8D). Serum NEFAs were not significantly different in male mice but 
trended lower in female KO mice fed a control diet (Fig. 8E). Finally, there were 
no changes in serum NEFA and serum TG (Fig. 8F), consistent with our previous 
work showing hepatic ACOT1 does not affect VLDL secretion.  
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Figure 8.  Acot1 knockout reduced hepatic TG. (A) Percent liver weight in 
male and female WT and KO mice fed a control or HFD and fasted overnight. (B) 
H&E and Oil Red O staining of hepatic tissue from male WT and KO mice. (C) 
ACOT1 KO in male and female mice reduced hepatic TG. (D) ACOT1 KO males 
on a HFD show significant increased serum β-hydroxybutyrate. (E) Serum NEFA 
is reduced with ACOT1 KO in male and female mice fed a control diet. (F) There 
was no significant difference in serum TG. *P<0.05 vs. WT. #P<0.05 vs. control 
diet. 
 
We next assessed expression of genes involved in hepatic lipid 
metabolism, including FA oxidation and FA synthesis. Male KO mice on a control 
diet had reduced expression of PPARα target genes, while the HFD significantly 
reduced expression of PPARα target genes in both WT and KO mice (Fig. 9A). 
Additionally, KO mice on a control diet had reduced PGC1α target gene 
expression. While HFD reduced PGC1α target genes in WT mice, Acot1 
knockout seemed to rescue this effect (Fig. 9B). These results suggest that 
ACOT1 is important for PPARα activity. Acot1 knockout also reduced the 
expression of genes involved in FA synthesis in mice fed a control diet, but not a 
HFD (Fig. 9C). These results suggest reduced hepatic TG could be in part driven 
by diet-specific mechanisms in Acot1 knockout mice. Male KO mice on a control 
diet have reduced hepatic TG due to reduced DNL, while males KO on a HFD 
have enhanced FA oxidation.  
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HFD is known to induce hepatic steatosis, but is not sufficient to increase 
progression of NAFLD including inflammation and fibrosis (25). However, acute 
Acot1 knockdown in the liver increases inflammation and fibrosis in the absence 
of steatosis. Since our current study also resulted in decreased hepatic steatosis, 
we next investigated hepatic ROS in our model. As expected, HFD increased 
hepatic ROS production, however Acot1 knockout reduced ROS in both diets 
(Fig. 9D). Similar to a reduction in oxidative stress markers, KO mice also had 
reduced inflammatory markers when fed a control diet. Surprisingly, we did not 
see an increase in inflammatory markers on a HFD as expected and KO mice 
exhibited a slight increase in these markers (Fig. 9E). Together these results 
suggest that whole-body Acot1 knockout reduces hepatic oxidative stress and 
inflammation in mice fed a control diet. 
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Figure 9. Acot1 knockout altered expression of genes involved in hepatic 
lipid homeostasis. (A) Hepatic PPARα target genes, (B) PGC1α target genes, 
and (C) FA synthesis genes in male WT and KO mice fed a control and HFD. (D) 
Hepatic ROS as well as (E) inflammatory gene expression. *P<0.05 vs. WT. 
#P<0.05 vs. control diet. 
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Discussion 
Ectopic lipid stores are a defining characteristic of obesity-related diseases 
including NAFLD and insulin resistance (2,5). Ectopic TG storage is not 
considered pathogenic, rather lipid intermediates contribute to the development 
of inflammation and insulin resistance (5,26). ACOT1 is responsible for the 
cleavage of long chain acyl-CoAs back to free FAs. As such, ACOT1 is believed 
to regulate the flux of lipid intermediates through metabolic pathways. However, 
the relevance of ACOT1 in adiposity, ectopic lipid accumulation, and subsequent 
development of NAFLD and insulin resistance has not been explored. Therefore, 
we investigated the effects of whole-body Acot1 knockout on adiposity and 
ectopic lipid metabolism.  
Male Acot1 knockout mice exhibited lower body weights throughout the 
study regardless of diet. Conversely, female mice exhibit similar weight gain on a 
control diet, however KO female mice were resistant to weight gain on a HFD 
(Fig. 2). These results suggest considerably different phenotypes between male 
and female KO mice. Metabolic cage studies were unable to elucidate a 
difference in energy expenditure in male mice fed a control diet, however, there 
was a trend toward increased energy expenditure in male KO mice fed a HFD 
(Fig. 4-5). There was also no observed difference in locomotion or food intake. 
The reduction in body weight was accounted for by reduced adiposity (Fig. 2E,F). 
Acot1 knockout correlated to smaller adipocytes in both epididymal and inguinal 
adipose depots (Fig. 3C-D). Previous groups have suggested that ACOT1 is 
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important for lipid accumulation during adipocyte differentiation (24), while others 
suggest upregulation of ACOT1 increases lipid storage (27). These results 
suggest that weight difference may be due to impaired lipid storage capacity with 
Acot1 knockout.  
Adiposity, ectopic lipid, and inflammation influence glucose homeostasis 
and insulin sensitivity. We observed slight glucose intolerance in KO mice, 
evident by OGTT (Fig. 6), yet KO mice had reduced adiposity (Fig. 3A), less 
hepatic lipid (Fig. 8B,C) and less inflammation (Fig. 9D,E). Therefore, impaired 
glucose tolerance seen in Acot1 knockout mice may be a result of impaired lipid 
intermediate metabolism. These results suggest that ectopic lipid is not essential 
to develop glucose intolerance, which is supported by other studies that uncouple 
TG accumulation from glucose intolerance and insulin resistance (28).  
Previously we demonstrated that hepatic Acot1 knockdown resulted in 
reduced hepatic TG in the fasted state due to enhanced FA oxidation. As 
expected, both male and female Acot1 knockout mice had reduced hepatic TG 
when fed a control diet and were protected from hepatic steatosis when fed a 
HFD (Fig. 8B,C). Hepatic lipid stores are influenced by uptake of NEFA, DNL, 
oxidation of FAs, or secretion of TG in VLDL. However, the observed decrease in 
hepatic TG was not fully explained by consistent changes in serum β-
hydroxybutyrate, serum NEFA, or serum TG across every group (Fig. 8D-F). As 
such, male mice fed a HFD have enhanced FA oxidation that may contribute to 
the observed reduced hepatic TG (Fig. 8D), an effect not observed in male mice 
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fed the control diet or female mice. These results were based on a snapshot in 
time and do not describe the flux of these metabolites through these pathways. 
Therefore we assessed RER in male mice to determine if KO mice had greater 
lipid metabolism, however there was no significant difference in RER (Fig. 5A-C). 
To further investigate lipid metabolism pathways, we measured gene expression 
involved in FA synthesis and FA oxidation in male mice. Acot1 knockdown 
reduced expression of FA synthesis genes and PPARα and PGC1α target genes 
on a control diet, but not a HFD. As such, male mice fed a control diet have 
reduced hepatic lipid likely due to reduced DNL (Fig. 9C). These results suggest 
that diet influences the mechanism by which Acot1 knockout is able to protect 
from hepatic lipid accumulation.  
Based on our current study, ACOT1 is involved in the development and 
pathogenesis of obesity and ectopic lipid storage. In the absence of ACOT1, 
mice were protected from adipocyte hypertrophy and hepatic lipid droplet 
accumulation. This phenotype correlated to reduced ROS production and 
expression of inflammatory genes, however exhibited slight glucose intolerance, 
suggesting that insulin sensitivity is affected by lipid species intermediates and 
not TG accumulation. Together, these results suggest that ACOT1 increases lipid 
storage potential in male and female mice fed a purified control diet or a 45% 
high fat diet. 
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The prevalence of obesity and obesity related diseases continue to rise in the 
United States. Currently over one third of all Americans suffer from obesity (1), 
contributing an extra $1700 to annual healthcare costs per person (2). Of the 
many comorbidities of obesity, NAFLD represents one of the most prominent as 
80% of all obese individuals have the disease (3). As such, it is speculated that 
as the rates of obesity climb in the United States so do the rates of NAFLD. 
Unfortunately, NAFLD is often undiagnosed and many patients go untreated for 
years leading to disease progression and greater liver damage (4). Outside of 
diet and exercise interventions that promote weight loss, there is currently no 
treatment for NAFLD. If the disease progresses to cirrhosis, damage can be 
permanent, requiring liver transplantation (5). As such, there is great need in 
understanding the metabolic pathways that propagate the progression of NAFLD.  
Thioesterases are highly conserved enzymes, exhibiting similar gene 
clusters in humans, mice, and rats (6). ACOT1 was first discovered in 1994 as 
the primary cytosolic thioesterase found in oxidative tissues (7). Since its initial 
discovery, the physiological importance of ACOT1 has been investigated in pre-
adipocytes (8), cardiomyocytes (9,10), and mesenteric lymph nodes (11). Our 
group is the first to investigate the importance of ACOT1 in hepatic fasting 
metabolism and whole-body lipid homeostasis.   
 Literature suggests that hepatic FA oxidation is governed by PPARα 
activity and expression of target genes (12). However, we observed increased 
FA oxidation in the absence of increased PPARα target gene expression during 
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acute Acot1 knockdown. Therefore, we suggest that ACOT1 creates the balance 
between FA oxidation and PPARα activity. Other groups have demonstrated a 
link between FA oxidation and ACOT1 driven expression of PPARα target genes. 
Liver-specific Cpt2 knockout mice have impaired FA oxidation resulting in an 
increase of cellular long chain acyl-CoAs. Acot1 expression is enhanced in this 
model to remove long chain acyl-CoAs by producing free FAs. Subsequently, the 
increased production of free FAs was suggested to increase PPARα target gene 
expression seen in liver-specific Cpt2 knockout mice (13). These results support 
the findings in our study that ACOT1 maintains the balance between lipid 
oxidation and PPARα signaling through mitigating the pool of acyl-CoAs to free 
FAs.  
 NAFLD is defined by hepatic steatosis, which then progresses to 
inflammation and fibrosis. However there are few disease states in which 
inflammation and fibrosis manifest in the absence of hepatic steatosis, including 
type III glycogen storage disease (14) and viral hepatitis (15). In our current 
studies, Acot1 knockdown reduced hepatic steatosis but increased oxidative 
stress, inflammation, and fibrosis. We demonstrate that Acot1 knockdown 
enhanced FA oxidation and subsequently increased gluconeogenesis (16). 
These results suggest that the cause of NALFD progression is not lipid 
accumulation in the liver, but the subsequent oxidation of excess lipid. 
Investigating the correlation between advanced NAFLD and these metabolic 
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pathways (17,18) provides insights into disease progression and identifies 
potential points of intervention to treat or prevent NAFLD.  
 Ectopic lipid storage is also correlated to the development of insulin 
resistance (19). Previous work from our laboratory and others have suggested a 
disconnect between hepatic TG and insulin resistance. Adipose triglyceride 
lipase knockdown prevents hepatic TG hydrolysis and sequesters TG in lipid 
droplets leading to massive accumulation of hepatic TG but protection from 
insulin resistance and glucose intolerance (20). Conversely, Acot1 knockout 
reduced ectopic lipid accumulation yet resulted in a mild glucose intolerance. 
These results were likely driven by dysregulation in lipid intermediates due to 
Acot1 knockout. These results support the current paradigm that inert TG 
accumulation in lipid droplets is not pathogenic, rather other lipid intermediates 
lead to insulin resistance (21).  
Unlike our results with acute Acot1 knockdown, chronic Acot1 knockout 
solicited a very different phenotype. Whole-body Acot1 knockout had reduced 
adiposity and hepatic TG, likely due to implications of adipocyte maturation and 
lipid utilization. Little research has investigated the role of ACOT1 in adipocyte 
differentiation. However, in brown adipocyte differentiation, Acot1 is expressed in 
the initial stages of differentiation where it is speculated to remove long chain 
acyl-CoAs from oxidation and promote lipid accumulation. Once differentiated, 
Acot1 expression reduces and Acot2 expression is enhanced (8).   
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Understanding the contribution of ACOT1 in adipocyte maturation may explain 
the discrepancy in body weight and observed adiposity. 
ACOT1 has previously been identified as a cytosolic protein (22–24). 
However, our research has shown ACOT1 to be a nuclear protein during 
prolonged fasting and under β-adrenergic stimulation. ACOT1 does not possess 
a known nuclear localization sequence. However, our studies suggest that 
ACOT1 translocation is dependent on PKA mediated post-translational 
modification. Nuclear Western blotting for ACOT1 identified a slight shift in 
ACOT1 protein size also suggesting nuclear localization may be driven by protein 
modification. In preliminary data, we explored potential phosphorylation sights of 
ACOT1, generating point mutations to mimic de-phosphorylation and 
phosphorylation, to determine their role in nuclear localization (data not shown). 
We were unable to confirm a specific phosphorylation sight that would explain 
the nuclear localization. Further studies are needed to determine the mechanism 
by which ACOT1 becomes nuclear.  
 In addition to ACOT1, there are other thioesterases that have had 
profound implications on metabolic health. ACOT13, a thioesterase found on the 
outer membrane of the mitochondria also regulates hepatic FA oxidation (25). 
ACOT13 produces free FAs on the mitochondrial surface rendering substrate for 
the ACSL1/CPT1α pathway for oxidation (26). Hepatic ACOT2 resides in the 
mitochondrial matrix where it also promotes the oxidation of FAs. Overexpression 
of Acot2 results in greater FA oxidation by mitigating the buildup of mitochondrial 
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long chain acyl-CoAs (27).  Lastly, ACOT7, a type II thioesterase found in the 
cytosol appears to play a minimal role in regulating FA oxidation in the liver 
however plays a critical role in adipose and neuronal lipid metabolism (28,29). 
Thioesterases are an understudied group of enzymes that play key roles in lipid 
trafficking and signaling. Future studies may provide great insights in the flux of 
lipid intermediates through metabolic pathways.  
 In summary, ACOT1 is a major regulator of hepatic lipid oxidation, 
removing acyl-CoAs from oxidation and providing nuclear FAs to activate 
PPARα. Together these roles regulate lipid intermediates, hepatic 
gluconeogenesis, and protects from oxidative stress, inflammation, and insulin 
resistance. Further studies will be needed to determine the exact mechanism by 
which ACOT1 translocates to the nucleus and its role in lipid storage capacity. 
Furthering our understanding of ACOT1 may shed light on the involvement of 
oxidative metabolism in the progression of NAFLD from simple steatosis to 
fibrosis and inflammation.  
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